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Autoimmune diseases afflict a significant part of the world population and current 
treatments only treat symptoms or delay the progression of the disease. In the first chapter of this 
dissertation, an introduction into autoimmunity and current clinically available non-antigen-
specific treatments was presented, along with an overview of the rise of antigen-specific 
immunotherapies (ASIT) as an improved strategy for the treatment of autoimmune diseases. 
Furthermore, a detailed background into the chemistry utilized in this work to construct novel 
antigen-specific probes as potential therapies for autoimmune disorders was also offered. A 
novel class of bioconjugates known as antigen-drug conjugates (AgDCs) have been developed in 
our group. AgDCs utilize a similar directing strategy as antibody-drug conjugates (ADCs), which 
use a protein or peptide autoantigen (vehicle) to direct a conjugated drug (payload) to antigen-
specific immune cells. Thus, AgDCs are a novel ASIT that may be used to treat autoimmune 
disorders. Chapter 2 is focused on the synthesis of various chemical biology tools, and the 
synthetic optimization of ‘clicking’ a modified-mimotope or a synthetic epitope to a potent drug 
via copper-catalyzed cycloaddition (CuAAC). This work also explored another potential novel 
therapeutic known as Soluble Antigen Arrays (SAgAs) developed in our group. SAgAs are 
constructed by using a hydrophilic linear polymer, hyaluronic acid (HA), grafted with multiple 
repeating autoantigen.  SAgA technology introduced tolerance and suppressed disease in several 
studies in the mouse model of Multiple Sclerosis. SAgAs were also designed for flexibility in 
accommodating other autoantigens and for facilitating screening of antigen valency effects. Two 
new type of SAgAs were constructed and characterized using different Type 1 Diabetes 
autoantigens, namely p79 (chapter 3) and human insulin (chapter 4). Both cSAgAp79 and 
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CHAPTER 1:  AUTOIMMUNE DISEASES, ANTIGEN-SPECIFIC IMMUNOTHERAPIES, AND 
COPPER-CATALYZED AZIDE-ALKYNE CYCLOADDITION (CUAAC) FOR BIOCONJUGATION 
1.1. Introduction to autoimmune disorders 
Over 80 identified autoimmune diseases are a result of an aberrant immune response 
targeting various organs, tissues, and cells.1 Over 5 % of the world’s population is afflicted by an 
autoimmune disorder and extensive efforts have gone into the development of therapies, but none 
have been successful in curing any of the diseases. Autoimmune disorders are believed to be 
caused by the loss of tolerance to self-antigen (autoantigen) and they typically develop through 
these three major phases: initiation, propagation, and resolution. Either genetic predisposition 
and/or environmental triggers in an individual often lead to initiation of autoimmunity. During the 
propagation phase, inflammation and tissue damage occur because of cytokine (soluble 
messengers that create tolerogenic or inflammatory responses dependent on their 
microenvironment) production, epitope spreading, and an increase in the accumulation of effector 
T cells. In addition, a decrease in Treg cells or an increase of dysfunctional Treg would also occur 
during the propagation phase, thus disrupting the Teff/Treg balance. Finally, resolution occurs 
when there is activation of cell-intrinsic and cell-extrinsic mechanisms that limit effector response 
and restore Teff/Treg balance.2 The targeting of self-antigens leads to various diseases such as 
rheumatoid arthritis (RA),3-8 multiple sclerosis (MS),9-11 type 1 diabetes (T1D),12-14 neuromyelitis 
optica,8,9 and lupus.10,11 Possibly by understanding similarities and differences between 
autoimmune diseases, novel therapies can be developed to regain tolerance.  
 Rheumatoid arthritis (RA) decreases the quality of life for 0.5-1% of adults of the world 
population. Individuals with RA suffer from CD4+ T cells, B cells and macrophages targeting the 
joint lining, known as the synovium, leading to inflammation, and proinflammatory markers lead 
to degradation of local cartilage and bone.3 Individuals with class II major histocompatibility-DR4 
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(HLA-DR4) alleles account for 70% of all RA patients.4 Foreign antigens, which share strong 
homologous peptide sequences with humans, are suspected as possible initiators to  RA. Examples 
of these foreign antigens include heat-shock proteins, Epstein-Barr virus (EBV) trans-actin factor, 
and Escherichia coli dnaj.5 The precise autoantigen that leads to the pathogenesis of RA is not 
known, however, the following autoantigens have been identified: Type II collagen, human 
chondrocyte glycoprotein 39, aggrecan, cartilage link protein, heat shock proteins, citrullinated 
filaggrin, immunoglobulin G, N-Acetylglucosamine-6-sulfatase, and filamin A.6,7 
 Multiple Sclerosis (MS) is a neurological disability that affects 2.5 million individuals 
internationally.8 The exact mechanism of disease progression is unknown for MS, but the current 
hypothesis is that the immune system incorrectly targets proteins, such as myelin basic protein 
(MBP) and proteolipid protein (PLP), which are located within the protective myelin sheath 
surrounding the neurons of the central nervous system (CNS). The inflammatory response leads 
to demyelination and progressive loss of motor functions.9 It has been reported that individuals 
with changes in HLA-DRB1 gene have the highest risk of developing MS.10 Environmental factors 
that increase an individual’s chance of developing MS include: EBV, smoking, and low levels of 
vitamin D.11  
 Type 1 Diabetes (T1D) is most commonly diagnosed among young children and young 
adults, affecting 2 in 1000. First, an abnormal immune response targeting beta cells in the pancreas 
leads to a reduction in insulin production. Insulin plays an important role in regulating blood sugar 
and fat storage. Second, a buildup of proinflammatory cytokines leads to further functional 
suppression on B cells resulting in elevated blood glucose levels. Finally, the regulatory control of 
the aberrant immune response fails, leading to further chronic destruction of B cells and complete 
loss of insulin production.12 The exact cause that starts the cascade of events that leads to the 
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development of T1D is not known. It has been reported that individuals with HLA-DR3-DQ2 
and/or HLA-DR4-DQ8 halotypes have a higher probability of developing T1D, accounting for 
90% of individuals with T1D.12,13 The cause for T1D for the remaining patients without genetic 
predispositions may be related to an yet discovered environmental factor12,14 Currently, the 
following autoantigens are implicated in T1D: insulin,15 non-specific islet cell (ICA),16 insulinoma 
antigen-2 (IA-2),17 and glutamic acid decarboxylase 65 (GAD-65).18 
   
1.2. Current treatment approaches for autoimmune disorders 
 Treatments for autoimmune diseases are categorized into the following four categories: 
general immunosuppressants, mobility and transport inhibitors, immune cell activation inhibitors, 
and antigen mimics. Most of these therapies are not antigen specific and cause global immune 
modification or inhibition, leading to an increase in susceptibility of being infected by a foreign 
pathogen. Immunosuppressants are effective for many individuals afflicted with autoimmune 
disorders, however, they have been shown to have toxicity problems and other adverse effects.19 
Mobility and transport inhibitors prevent auto-reactive immune cells or antibodies from migrating 
to their site of action; however, these classes of therapies also suffer from adverse side effects that 
result in retraction of immune cells that may be needed to fight off foreign pathogens.20 Immune 
cell activation inhibitors work by blocking costimulatory pathways required for an antigen-specific 
immune response. It has been reported that the lack of costimulation can inhibit immune activation 
and move the immune response toward tolerance.21-23 Antigen mimics aim to induce an antigen-
specific immune response without anaphlaxysis that can be associated with the native antigen.24 A 
few of examples of each category will be highlighted. 
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 Two small molecules teriflunomide (Aubagio) and lefunomide (Arava), to treat MS and 
RA respectively, are anti-inflammatory compounds that inhibit immune cell proliferation by 
blocking the synthesis of DNA necessary for cell division.25 The pathway for pro-inflammatory 
cytokine IL-2 can be disrupted by the small molecule ciclosporin, which is used in the treatment 
of RA and T1D.26 Glucocorticoids, such as prednisolone and prednisone, are meant to treat RA 
and SLE, however the mechanism of action is not known.  These class of drugs show promising 
pleiotropic immunosuppression but they may reduce the robustness of the immune response by 
reducing the expression of cellular receptors.27 The above examples and other global immune 
suppressants all lack specificity and do not cure the disorder but only manage symptoms by 
reducing damage done by the immune system.26, 28 
 The monoclonal (mAb) antibody natalizumab (Tysabri), approved by the FDA in 2004, is 
used to treat MS by targeting vascular cell adhesion molecule-1 (VCAM-1). Natalizumab inhibits 
binding of cell adhesion molecules and decreases the number of auto-reactive T-cells in the CNS 
tissue through reducing leukocyte trafficking across the blood brain barrier.20 In addition, the 
mobility and transport inhibitor efalizumab (Raptiva) is an anti-LFA-1 antibody used to treat 
chronic psoriasis.21 Both natalizumab and efalizumab have been shown to cause progressive 
multifocal myelencephalopathy (PML), which led to their removal of approval and withdrawn 
from clinical use, respectively. Upon determination of JC virus antibodies as risk factors for the 
development of PML in individuals with MS, for those who did not test positive for the JC virus, 
natalizumab was reapproved in 2006 as a last resort treatment.29 Several other mAb meant to target 
CD20 to help treat autoimmune disorders, such as, veltuzumab, TRU015, ocrelizumab, and 
ofatumumab, are currently being studied in the clinic. 30 Immune cell activation inhibitor such as 
rituximab (Rituxan), is a chimeric IgG1 anti-CD20 mAb meant to target B-Cell activation, has 
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been approved for the treatment of MS, RA, and SLE.31 Clinical success has been seen for B-cell 
depletion by rituximab in both MS31 and SLE32. T-cell mediated autoimmune disease have been 
targeted with biologicals such as abatacept (Orencia) for RA, T1D, SLE, and psoriasis. Abatacept 
is a biological, CTLA-4 IgG1 fusion protein meant to target the B7 pathway, which leads to 
tolerance to antigen or immunosupresion.33-34  In addition, belatacept (Nulojix) is also used to treat 
RA and T1D have been approved by the FDA.33 Belatacept is another biological, CTLA-4 
IgG1fusion protein that has been shown to have even greater binding affinity to B7 than 
abatacept.34 Neither biological is antigen-specific in their B7 pathway inhibition. Alternatively, 
the small molecule fingolimond (Gilenya) used to treat MS patients worked by inhibiting the 
internalization of S1P-receptor on immune cells, thus preventing autoreactive lymph nodes from 
trafficking to the CNS.25 
 
1.3. Antigen-specific immunotherapy (ASIT) 
 In order to combat the lack of specificity of the previously mentioned therapies, scientists 
have begun implementing the use of autoantigen delivery systems to induce an antigen-specific 
immune response for the treatment of autoimmune diseases. Antigen-specific immunotherapy 
(ASIT) are designed to treat specific autoimmune diseases by using implicated autoantigen.35 The 
most successful ASIT, hyposensitization therapy, has been used to treat allergies by  inducing an 
antigen-specific immune response to induce tolerance.36 Occasionally, some hyposensitization 
therapy can lead to life threatening anaphylaxis, thus requiring a trained professional to administer 
treatment. Since hyposensitization therapy is a successful example of ASIT, similar approaches 
have been used to develop ASIT for autoimmune diseases.35, 37-38 
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 A ‘decoy’ strategy, known as antigen mimics, is meant to induce an antigen-specific 
immune response by drawing the attention of the immune system away from the native antigen. 
Antigen mimics, insulin and insulin analogous have been used in the treatment of T1D but clinical 
trials have not been successful.24 Similar to antigen mimics, altered peptide ligands (APLs) have 
emerged as a therapeutic subclass. They are composed of amino acids from the native antigenic 
epitope but with substituted amino acids. A polymer therapy known as glatiramer acetate 
(Copaxone®) was designed to emulate MBP epitopes and has been approved to treat MS. It is 
hypothesized to be a competitive MHC class II molecule that causes a T-helper type 2 immune 
response and it may be an antagonist for MBP specific T cells.39-40 Thus, possibly making the 
mechanism of action both antigen-specific and non-specific in its effect on the immune response. 
However, further studies are required to obtain a better understanding of the mechanism of action.  
 The Dintzis group reported that in order to induce tolerogenic immune responses, the 
antigen-delivery vehicle must include certain antigenic (peptide antigen length/size and target 
affinity) and pharmaceutical (size, hydrophilicity and stability) characteristics.5-8 Many antigen-
specific immunotherapies exhibit characteristics similar to traditional vaccines. Vaccines are 
designed to initiate a directed adaptive immune response to specific antigens to provide a robust 
“protective” immunological response upon re-challenge. This is accomplished by co-delivering 
antigen in an adjuvanted matrix, typically comprised of insoluble alum particulates. Vaccines often 
contain particles within the size range of 1- 10 µm and are postulated to form a depot at the 
injection site, providing a high local concentration of antigen and initiating specific recruitment of 
immune cells. Additionally, these insoluble adjuvants make the adsorbed antigen more particulate 
in nature, comparable to that of a virus or bacteria, and help enhance antigen recognition and 
uptake, and thus more readily undergo phagocytosis by antigen-presenting cells (APCs). 
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 Conversely, allergy shot therapies commonly use soluble allergens to hyposensitize the 
immune response and establish tolerance.9 This is typically accomplished by delivering low doses 
of soluble antigens via subcutaneous injection over an extended period of time. These allergen 
antigens tend to be much smaller (< 50-70 kDa) than the much larger particulate vaccines and are 
not delivered as part of an adjuvanted matrix. Interestingly, these characteristics of the allergens 
would be conducive to transport and draining into lymph nodes. Allergen-specific 
immunotherapies are known to hyposensitize immune responses, thus providing a benchmark for 
design of autoimmune ASIT delivery systems that has yet to be explored. Traditional allergen 
desensitization requires multiple treatments over an extended period of time, typically months to 
years. Recent allergen desensitization approaches have investigated intranodal injection of ASIT 
and results have shown that it is a highly efficacious, safe, and reduces the treatment duration 
dramatically, sometimes to as few as 3 injections.10 
 
1.3.1. ASIT by means of combination strategies for autoimmunity 
Combination strategies for ASIT have emerged as a way to combine the specificity of 
antigen-only therapies and potency of immunomodulators. Two different combination strategies 
exist to treat autoimmunity, either by co-administration or via co-delivery. Co-administration 
therapies allow for the flexibility of dosing different compounds (i.e. an antigen and an 
immunomodulator) in similar period of time and frequently by the same route of administration 
without a co-delivery vehicle. Co-delivery ASIT, either chemically or physically, keeps both the 
immunomodulator and antigen near one another, thus, delivering both components at the same 
time and into the same environment. 
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The Kang group reported the use of a co-administration approach by co-injecting the small 
molecule immunosuppressant dexamethasone (Dex) and the antigen ovalbumin (OVA), which 
were able to cause long-term antigen-specific tolerance in T1D murine model.41 The same group 
later reported co-injecting Tacrolimus (FK-506), an immunosuppressant, along with a plasmid 
DNA encoded with autoantigen. Their co-administration strategy resulted in the expansion of 
Tregs and thus treating autoimmunity.42  Co-administration is not limited to small molecules,  
biologics have also been reported to be used in co-administration ASIT. The majority of these 
therapies use a plasmid encoding an immunomodulatory biologic component and a plasmid DNA 
encoding autoantigen. Glinka and coworkers reported the use of a plasmid encoding a fusion 
protein composed of preproinsulin (PPI) and Glutamate decarboxylase 65 (GAD65), which are 
both suspected autoantigens associated with T1D, and plasmid encoding an immunomodulator 
compound mutant B7, a known CTLA-4 inhibitor. This co-administration therapy was reported to 
improve the disease state of non-diabetic mice (NOD). Other have reported similar therapies such 
as the Garren group and Lewis group for MS43 and T1D44 respectively. Drawbacks to co-
administration ASIT include the non-specific immune suppression by rouge immunomodulator or 
complete loss of efficacy if the autoantigen and immunomodulator drift away from the 
microenvironment meant to be targeted.  
Co-delivery addresses the major drawback associated with co-administration for the 
treatment of autoimmunity by the using a co-delivery vehicle that insures the delivery an 
immunosuppressant and autoantigen at the same time and microenvironment. This strategy can be 
broken up into three distinct categories for the delivery of autoantigen and an immunosuppressant: 
first, plasmid DNA can co-encoded both components; second, the components are absorbed or co-
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encapsulated; and finally, an autoantigen and immunosuppressant can be chemically linked 
together.  
A single plasmid DNA encoding the autoantigen GAD65 and the immunomodulator IL-
445 or the pro-apoptotic protein BAX,46 have been co-delivered as a treatment for NOD mice, a 
T1D mouse model mimic. Both of these co-delivery therapies have been successful in the 
suppression and prevention of the disease.45-46 Numerous types of particulate  delivery vehicles 
(ie. liposomes,47 nanoparticles,48 microparticles49) either co-absorb or co-encapsulate autoantigen 
and immunosuppressants for the treatment of autoimmune diseases. The co-delivery by co-
encapsulation of Dex and the MS autoantigen MOG35-55 in acetylated dextran nanoparticles were 
reported to improve the disease state of EAE mice.49 When compared to co-administration work 
by Kang and coworkers41 with the same autoantigen and immunosuppressant in the same mouse 
model, the co-delivery treatment was shown to be more efficacious.49 Finally, bifunctional peptide 
inhibitors (BPIs) such as PLP chemically linked to ICAM-1, a cell adhesion molecule, has been 
shown to improving the disease state in a MS animal model;50 and the BPI GAD65 chemically 
linked to CD11a237-247, an  immunomodulator, helped reduce immunogenicity in a T1D
51 mouse 
models. A drawback for co-delivery ASIT is the requirement of a delivery vehicle for an 
immunosuppressant and an autoantigen, since the delivery vehicle may be difficult to be 
formulated, encoded, or conjugated. This work will focus on the bioconjugation of autoantigens 
to an immunosuppressants and the synthesis of a novel antigen-only delivery system for the 
treatment of autoimmunity, and therefore, a brief review and explanation of bioconjugation 




1.4. Introduction into Bioconjugation  
In 2001 the Sharpless group—inspired by nature’s ability to produce enormous biological 
diversity from a limited number of monomers—proposed the development of a set of robust, high 
yielding, selective, and broad ranging methods that can be performed under benign reaction 
conditions  for coupling molecular fragments together.52 Sharpless coined this class of reactions 
“click chemistry,” a strategy which supplied a library of molecules with selectively-reactive 
handles for efficient synthesis of various conjugates. This convenient and efficient synthesis 
strategy allows for rapid construction of various bioconjugates or non-biological molecules to 
probe and reveal new information about biological systems or cause a desired biological effect 
(i.e. via an ASIT). The selectivity of click chemistry encouraged Bertozzi and co-workers to apply 
the strategy in living systems and develop “bioorthogonal” reactions.53 
Several click reactions are present in the literature, such as Diels-Alder,54 Staudinger 
ligation,55 thiol-Michael addition,54, 56 oxime ligation reactions,57 and copper-catalyzed azide-
alkyne cycloaddition reaction (CuAAC) to name a few. CuAAC is the most widely applied click 
reaction that has been developed. Various disciplines have applied this highly efficient coupling 
reaction for the synthesis of drugs, biomolecules, polymers, advanced biomaterial, and surfaces. 
Strain-promoted azide-alkyne cycloaddition reaction (SPAAC) was developed to improve upon 
the disadvantages of CuAAC by eliminating the need for copper, thus eliminating cell toxicity and 
allowing the reaction to become biorthogonal.  
This work utilizes azide-alkyne cycloaddition (AAC) reactions for the synthesis of ASIT 
and therefore a literature review of the history, reaction conditions, methods for installation of 
reactive handles, and utilization in peptide or protein bioconjugates, with an emphasis on practical 
examples as well as challenges and limitations with this approach, will be covered.  Finally, a 
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section outlining the trends of non-AAC linkers, which was extrapolated in our implementation of 
AAC chemistry bioconjugation will be discussed. 
 
1.5. Azide-Alkyne Cycloaddition Reaction  
In 1961 Huisgen was the first to report the formation of 1,2,3-triazoles via AAC (Table 
1).58 This heterocyclic bioisostere—a chemical group or substituent with similar chemical or 
physical properties to another substituent or group—is a potential replacement for an amide. 1,2,3-
triazole’s are more resistant to enzymatic degradation, oxidizing or reducing conditions, and pH. 
Specifically, the 1,4-substituted triazole constitutional isomer, is similar to an E-amide in both 
electronic properties and topology; the triazole isomer exhibits spacing of  5.0 Å as compared to 
3.9 Å in the E-amide bond;59it also has a dipole moment of 5 Debye as compared to 4 Debye in 
the amide.60 The 1,5-substitued triazole and Z-amide are geometrically analogous because they 
both have a bond distance of 2.4 Å.61  While the triazole ring is appealing, the Huisgen reaction is 
limited in its application because of its drawbacks: lack of regioselectivity, elevated pressure, high 
temperatures, and long reaction time required to furnish a triazole mixture (Table 1). 
Both the Sharpless52 and Meldal62 groups simultaneously and independently reported the 
use of catalytic amounts of Cu1+ led to regiospecific formation of 1,4-substituted triazoles under 
mild reaction conditions. In the absence of Cu, they reported rates 106-107 times slower in 
producing the mixture of 1,4- and 1,5-substituted products. The reaction can be performed at 
various temperatures (0-160 °C), in numerous solvents (including water), and at a wide range of 
pH values (4-12).63-67 During the initial application of the CuAAC reaction, several drawbacks 
where discovered, where the problems were predominately associated with Cu.  The active catalyst 
in CuAAC reaction is Cu1+, which can be oxidized to the more stable Cu2+ in solution. To counter 
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this problem, Cu2+ is used with excess reducing agent to make Cu1+ in situ. The most common 
reducing agent used for CuAAC is sodium ascorbate in a 3- to 10-fold excess relative to Cu.68 
Other reducing agents, such as hydrazine69 and hydroxylamine,70 have also been used. Sodium 
ascorbate and Cu1+ however, have been reported to promote the oxidation of histidine and arginine 
residues.71 These unintended side reactions have led to the introduction of Cu-stabilizing ligands 
(Table 1) to both limit degradation of these amino acids, as well as, to accelerate the rate of the 
CuAAC reaction.72-73 The drawback of the toxic effect of Cu on cell viability has limited its use. 
Finally, the inability to perform CuAAC reactions in biological systems, due to the need of Cu, 
has restricted it use as a possible bioorthogonal reaction. 





































* Examples of Cu-
stabilizing reagents 
commonly employed in 
the CuAAC reaction 
 
R = benzyl (TBTA) 
R = tert-butyl (TTTA) 
R = CH2CH2CH2OH (THPTA) 
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To address the problems associated with CuAAC, Bertozzi and co-workers developed the 
SPAAC reaction in 2004 (Table 1).74 This method does not require a catalyst because it uses the  
high degree of ring strain on the cyclooctyne ring (18 kcal/mol) and lowered activation energy due 
to the favorable geometry of the starting materials being similar to the transition state (sp2 like in 
structure). Thus, the reaction is facile and works under mild reaction conditions and relatively fast 
reaction times.75 However, the SPAAC has its own drawbacks, such as the lack of regiospecificity 
due to the absence of strong kinetic or thermodynamic preferences leading to a mixture of 1,4-
substituted products. The aqueous solubility of the hydrophobic cyclooctyne reagents were of 
concern, but recent developments have seen the installation of hydrophilic moieties, such as 
polyethylene glycol (PEG) or sulfonate groups in the linker attached to the ring. Strained 
cyclooctyne reagents were initially cost-prohibitive to employ compared to their terminal alkyne 
counterparts. Alternative SPAAC reagents and synthetic routes76 have recently been reported, thus 
making the reagents more cost effective. With greater access to SPAAC reagents, a number of 
strained alkyne moieties have been developed with varying reaction rates.77 Photolabile “caged” 
cyclooctyne variants present an important added functionality to the reaction, revealing the 
reactive strained alkyne group under exposure to 350 nm light and enabling spatially-controlled 
conjugation (Figure 2A).78 These reagents have predominately been used for surface 
functionalization applications where spatiotemporal control of conjugation is critical.79-80 
Regioselective formation of 1,5-substituted triazoles has also been reported by the use of 
catalytic ruthenium (Ru) complexes.81-86 Compared to Cu catalyst, Ru catalyst can uniquely react 
azides with internal alkynes.87 Both steric and electronic considerations for the synthesis of 1,5-
triazole have to be examined. The 1,5-triazole mimics the Z-amide bond, which is 
thermodynamically unfavorable compared to the E-amide bond due to steric repulsion of the 
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groups flanking the amide moiety. The value of the triazole as an amide bond surrogate relies on 
the oxygen lone pair, the acidic N-H bond and the polarized carbonyl carbon. The polarization of 
the 1,5-triazole, however, is such that the electrophilic carbonyl carbon is replaced by a negatively 
polarized nitrogen atom.88  Therefore, despite the ability of Ru to catalyze reactions between 
internal alkynes and azides, the dissimilar electronic properties and unfavorable steric interactions 
compared to the naturally-occurring amide bond limits the implementation of Ru in bioconjugation 
approaches to make bioisostere of amides.89  The facile synthesis of the 1,4-substituted triazole 
ring via AAC, and its stability and chemical properties has led to its implementation in 
bioconjugation applications. In order to exploit the utility of the triazole ring, one must first 
understand various ways to introduce reactive handles to molecules of interest, which will undergo 
subsequent AAC reactions. 
 
1.6. Installation of Azide and Alkyne Functionalities on Intact Biomolecules 
Two common approaches are used to functionalize biomolecules with azide or alkyne 
handles: N-hydroxysuccinimide (NHS) coupling reaction and thiol-maleimide reactions (Figure 
1A, 1B). NHS ester mediated amide bond formation using an amine and carboxylic acid and are 
among the most popular compounds used to functionalize biomolecules due to their aqueous 
compatibility, commercial availability, and the ability to selectively target primary amines present 
on lysine residues or the N-terminus (Figure 1A). For biomolecules, reaction conditions generally 
employ aqueous buffers at pH 7-9. At a pH closer to 9, the reaction proceeds more efficiently due 
to greater amine deprotonation. However, at elevated pH, hydrolysis of the activated NHS ester 
also occurs at a greater rate. Conversely, at neutral pH, the reaction between primary amines and 
NHS esters proceeds with reduced hydrolysis of the NHS ester, but the reaction occurs at a slower 
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rate. Thus, a pH between the range 7-9 is commonly employed to balance the reaction rate and 
hydrolysis rate of the NHS ester. Typically, NHS esters reactions are performed at room 
temperature over 1-2 hours. Reactions involving sensitive biomolecules can proceed at 4°C 
overnight, in order to minimize or eliminate degradation. 
Selective N-terminal functionalization has been shown at pH values below 7, with pH 6.3 
being ideal. This is due to the difference in acidity between the α-amino group of the N-terminus 
(pKa ~ 8) and the ε-amino group of lysine 
residues (pKa ~ 10).
90 Amine-containing buffers 
such as tris or glycine must be absent, however, 
these can be useful as quenching buffers to 
ensure no additional reactive NHS ester is 
available after achieving the desired degree of 
functionalization. NHS ester reagent solutions 
should be prepared in anhydrous organic 
solvents to limit hydrolysis prior to initiating the 
reaction, provided that all reaction components 
remain compatible. However, excess NHS ester 
reagent can be use in anhydrous organic 
solvents.  Unfortunately, NHS ester reagents are 
typically not stable for more than a few hours in 
solution, even when prepared in anhydrous 
solvents. Thus, if the NHS ester reagent is the 
limiting reagent, anhydrous solvents should be used to maximize yield. 
Figure 1: General reaction schemes to functionalize 
biomolecules with azides and alkynes. 
17 
 
For NHS ester-containing small molecules that do not require aqueous solvents to dissolve, 
it is best to use anhydrous organic solvents such as N,N-dimethylformamide (DMF), dimethyl 
sulfoxide (DMSO), acetonitrile (MeCN), and dichloromethane (CH2Cl2). The reduction of the 
possibility of aqueous hydrolysis generally results in higher yields and better selectivity for amino 
functional groups. In the absence of an amine, NHS esters can be used to conjugate other 
nucleophilic groups such as deprotonated hydroxyl or thiol moieties. Finally, coupling between a 
nucleophilic moiety (i.e. amines, thiols, alkoxides) and a carboxylic acid can be achieved by 
forming an NHS ester in situ. First, by either using the coupling reagent 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) or N,N’-dicyclohexylcarbodiimide (DCC) to modify 
the carboxylic acid, then by adding NHS to form the NHS ester in situ, and finally by adding the 
nucleophilic component to produce the amide bond  to connect the two components. (Figure 1B). 
The thiol-maleimide reactions can be used when a cysteine residue is present in a 
biomolecule. This reaction yields a thioether bond via a Michael addition reaction (Figure 1C).  
Thioethers have been reported to undergo thiol exchange reactions, as well as to convert back to 
the starting thiol and substituted maleimide.91 Similar to the NHS ester reactions, maleimide 
reactions are pH-controlled in aqueous media. Generally, the pH range of 6-8 and at lower pH 
values, the reaction proceeds at a slower rate, but favors thiol functionalization over hydrolysis. 
However, at higher pH values, the reaction proceeds at a faster rate, but hydrolysis of the 
maleimide is of greater concern. Thiol-containing reaction buffers, such as dithiothreitol (DTT) or 
β-mercaptoethanol (BME), should be avoided, but are useful post-reaction to quench any 
remaining maleimide after achieving the desired conjugation levels. Mechanistic studies have 
revealed three main factors that affect the thiol-maleimide reactions: solvent, initiator (base), and 
the thiol selected.92   
18 
 
Biomolecule functionalization with the goal of attaching an azide or alkyne are most 
commonly performed using NHS ester or thiol-maleimide chemistry. There are a variety of 
commercially available heterobifunctional linkers other than just NHS esters or maleimides shown 
in Figure 2. Such monomers can be used for the following four major areas: final N-terminus 
functionalization during peptide or protein synthesis, residue-specific functionalization, post-
translational modification, and nucleic acid modifications.   
 
1.6.1 Unnatural amino acid Strategies for Azide-Alkyne Instillation 
Selectivity and reproducibility of bioconjugation via NHS ester or maleimide chemistries 
on larger proteins have proven to be challenging,  since the surface-exposed lysine and cysteine 
residues targeted can be abundant on larger proteins.87, 93 To overcome the challenge, unnatural 
amino acids (UAAs) bearing azide or alkyne functionalities (Figure 2C)54-56, 94 have been used in 
solid-phase peptide synthesis (SPPS) or by metabolic labeling during expression in cell systems, 
respectively. UAA modifications are generally divided into site-specific and residue-specific 
categories. Site-specific functionalization refers to the modification of a single amino acid, 
whereas residue-specific functionalization allows for partial or quantitative replacement of a 
particular amino acid. For smaller peptides, site-specific functionalization using SPPS is relatively 
simple. A wide range of UAAs are commercially available with both azide and alkyne functional 
groups and protected versions of these compounds (Figure 2B) can be used to enable selective 
incorporation of the desired handle during SPPS.58 In residue-specific labeling, UAAs are included 
in cell growth medium and incorporated into the primary sequence of the expressing protein. In a 
review, Budisa et al.95 outlines the biology of the metabolic labeling methods, as well as, some 
issues that arise with the incorporation of UAAs. Peptides bearing azide and alkyne handles also 
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present an attractive way to make cyclic peptides, which have literature precedence.57, 60, 96 Site-
specific installation of click reactive handles has been utilized for many functions such as fatty 
acid conjugation,66 conjugation of an antibody to a drug,67-68 or for fluorophore labeling of a 
protein.72 
Figure 2. Commercially-available materials for biomolecule functionalization via azide or alkyne reactive handles. 
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1.6.2. Heterobifunctional Linker, Post-Translation, and Nucleic acid Modifications 
 Installation of azide or an alkyne can also be achieved with the desire for reactive handles 
using heterobifunctional reagents such as modified sugars, or nucleic acids. Heterobifunctional 
reagents are selected when the C-terminus amino acids of a peptide or protein are required to 
maintain activity. They are installed on the N-terminus as the final step of SPPS.  Since these 
linkers do not contain a nucleophilic functionality such as a primary amine, there is no need for 
the use of protecting group chemistry. The heterobifunctional linker generally contains a 
carboxylic acid moiety on one end and on the other end either an azide or alkyne handle (Figure 
2D). In order to alleviate potently increased hydrophobicity upon installation of a 
heterobifunctional linker, a variety of heterobifunctional linkers are commercially available with 
different solubilizing groups such as PEG and sulfate groups. PEGylated forms of the 
heterobifunctional linkers are available in various lengths, which permits precise spacing of the 
reactive handle.  
 Post-translational glycosylation has been exploited as a meant for site-specific conjugation 
during protein expressed in cell systems. For example, modified acetylated sugars may be added 
to growth medium, which first needs to be internalized by host bacteria, followed by the removal 
of the acetate groups by non-specific hydrolases or esterases prior to being available for 
incorporation into the protein sequence (Figure 2E). Upon incorporation of a sugars into proteins, 
‘click’ chemistry can be performed either in vitro or following protein isolation.79-81, 83, 85-86 
Similarly, incorporation of alkyne-modified fatty acids can be done during other biosynthetic 
pathways such as post-translational lipidation, prenylation, farnesylation,78, 80, 82, 84, 87, 89 (Figure 
2Fi) or isoprenoid precursors87-88, 90 (Figure 2Fii). Protein and fatty acid incorporation of AAC 
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handles is also useful for the facile conjugation to AAC fluorophores (Figure 2H), which allows 
for direct measurement of biological activity. 
 DNA,58, 60, 91 RNA,59  and components on a cell membrane60 can also have modifications 
to install azide and alkyne nucleic acids (Figure 2Gi-ii) and cell surface molecules. (Figure 2Giii-
iv). These modifications are primarily used for imaging applications. However, such modifications 
can be used to enhance targeting, alter binding,58 or modify expression to provide significant 
therapeutic potential. Neef and co-workers59 reported that an unnatural nucleic acid in DNA 
labeling resulted in a difference in incorporation efficiency and toxicity. However, they postulated 
that the difference was possibly due to the particular cell type used in their studies. 
 
1.7. Payload Molecules for Probing or Modulating Biomolecule Function 
In order to study biological function in real time, both azide and alkyne modified 
fluorophores (Figure 2H) and radiolabels (Figure 2I) have been reported. Predominately, 
biomolecules are tagged with a fluorescent component for imaging inside of a cell and/or 
quantitation using techniques such as flow cytometry. Sivakumar et al.97 developed a pro-
fluorescent hydroxyl-coumarin molecule (coumarin-N3, Figure 2H), which had insignificant 
fluorescence when unconjugated, and became fluorescent upon successfully AAC by the 
formation of the extended conjugated system.98 Due to the fluorescent hydroxyl-coumarin pro-
fluorescent quality, various studies utilized the fluorophore to optimize the reaction and to study 
kinetics of the click reaction.99-100 Similarly, radiolabels (Figure 2I) have been reported and used 
to enable access to both targeted radiotherapy and in vivo visualization and quantitation techniques 
that are not possible with fluorescent labels, such as positron emission tomography (PET)101 and 
single photon emission computed tomography (SPECT).102 In order to modify clearance or alter 
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biodistribution, PEGylation reagents (Figure 2J) can also be utilized by making significant changes 
to its molecular weight (MW), and thus significantly changing the biophysical properties of the 
bioconjugate. Van Geel and coworkers.69 reported that AAC reaction efficiency can be increased 
by increasing PEG chain length, up to 12 units.  
AAC chemistry has also been utilized in the field of biopharmaceutics as a facile method 
for the synthesis of antibody-drug conjugates 
(ADCs). Currently, ADCs used clinically or in 
clinical trials utilize thiol-maleimide chemistry 
to bioconjugation. Unlike AAC, this process 
thiol-maleimide chemistry is reversible and is 
not as specific as AAC reactions. This lack of 
specificity for thiol-maleimide chemistry leads 
to heterogenous product mixture.103 In order to 
improve efficacy of ADCs that use thiols for 
bioconjugation, both site-specific modification 
and improved stability have been 
implemented.104 In order to further improve 
ADCs, scientist are exploring click chemistry for 
conjugation of payloads to antibodies. Azide or 
alkyne functionalized UAA have been 
incorporated into antibodies then conjugated to 
an azide or alkyne functionalized payload59-60, 104 using a variety of linker types including a 
cleavable linker.60 Cytotoxic drugs auristatins and maytansinoids, commonly used in ADCs, have 




been functionalized with handles for AAC chemistry (Figure 3). Currently, Twenty-two of the 
ADCs currently in clinical trials or on the market incorporate monomethyl auristatin E (MMAE) 
or monomethyl auristatin F (MMAF).103 Similarly, the maytansinoids are used in 13 ADCs either 
in the clinic or commercially-approved.103 Heterobifunctional linkers (Figure 2D) have also been 
used to functionalize the payload molecule.1, 103 The incorporation of azide-UAAs into a 
monoclonal antibody (mAb) allows for site-specific conjugation of modified payloads,58-60 but 
requires careful optimization for each payload, linker, and mAb.59 Another approach which does 
not alter the primary sequence exploits post-translational modifications by attaching click handles 
onto glycans of the heavy chain.69, 100, 105-106 More information on payload conjugation in click 
chemistry and in ADCs can be found in Meyer et al.,107 Beck et al.,103 and Akkapeddi et al.108 
 
1.8.  Challenges Associated with Bioconjugates: Synthetic and Analytical Considerations 
Bioconjugates can exploit the benefits of multiple molecules with different properties, but 
their complexity often brings new challenges with respect to the synthesis and analysis of these 
constructs. Synthetic complications typically center on solubility or stability of the parent 
molecules or resulting conjugate. Proteins and other biomolecules are generally more sensitive 
than the payload to temperature and other environmental factors such as organic solvents, thereby 
limiting the approaches available to the traditional synthetic chemist.6,109 In addition to reaction 
condition considerations, analytical hurdles reside around heterogeneity, deconvolution of data, 
and limited sample quantities due to high costs of proteins, which requires adaption of methods 
and techniques to comply with these demands.  
Solubility of the biomolecule and payload are required for the success of the conjugation 
reaction. Payload molecules with minimal aqueous solubility require assistance from an organic 
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solvent to ensure the conjugation reaction can proceed. Typically, DMSO, DMF, and MeCN are 
used in these situations. However, one must also bear in mind the effect of organic solvent on the 
biomolecules. Biomolecules with higher order structure can be conformationally altered in the 
presence of organic solvents and may have limited solubility as the organic concentration 
increases. Therefore, minimizing the overall organic solvent concentrations used in the reaction is 
often essential.6,110 As covered previously, NHS ester and related chemistries which target surface-
exposed lysines or other charged amino acids can have a great impact on the overall solubility of 
the product as these amino acids will lack a charge following conjugation, thereby decreasing 
solubility of the bioconjugate. To negate some of the deleterious effects of conjugation on 
solubility, linkers which have solubilizing moieties can either counteract or enhance solubility as 
desired in the conjugate.   
Importantly, a thorough understanding of the stability and degradation mechanisms of the 
parent molecules will guide the chemist in selecting the appropriate reaction conditions while 
maintaining the integrity of the functional entities involved. These studies must assess both the 
physical and chemical stability of the molecules, since mechanisms leading to instabilities in small 
molecules are different than those seen for larger biomolecules. Proteins have a frequent 
propensity to aggregate in solution, a phenomenon which can be reversible or irreversible. 
Aggregation can be especially problematic during synthesis, leading to precipitation and lower 
yields if not properly controlled. Aggregation during a chemical reaction can generally be limited 
by excipient addition, modification of the reaction environment (pH or ionic strength), decreasing 
reaction temperature, and limiting the amount of time the biomolecule is in solution. Any 
aggregates that form during the reaction should be separated from the product prior to final 
isolation, typically by filtration, centrifugation, or other size exclusion methods. Analytical 
25 
 
techniques employed for studying aggregation in biomolecules include size exclusion 
chromatography (SEC), gel electrophoresis, or various spectrophotometric and light scattering 
particle sizing methods appropriate for the aggregate size involved. Liquid chromatography 
coupled with tandem mass spectrometry (LC-MS/MS), often preceded by enzymatic digestion, is 
a powerful technique for understanding chemical degradation products in biomolecules. Small 
molecules are generally more robust than biomolecules and the degradation products can be more 
easily understood using LC-MS and NMR techniques. When designing bioconjugates that utilize 
the AAC reaction, the chemical and physical stability of the biomolecule, linker, payload, and any 
intermediates or catalysts must be taken into consideration and monitored appropriately. 
Purification of bioconjugates constructed via the AAC reaction often require additional 
considerations. When employing the CuAAC variant, residual Cu is undesirable in the final 
products due to the toxic and oxidative effects in living systems. Fortunately, removal through 
common techniques appropriate for the compounds involved is generally adequate. For small 
molecules, Cu-binding resins such as Cuprisorb or chelators such as ethylenediaminetetraacetic 
acid (EDTA) are added following the reaction, which can also serve to quench the reaction.6 
However, metal binding resins such as Cuprisorb have a tendency to bind to biomolecules and 
should be avoided during purification. Purification for peptides and proteins is typically completed 
by chromatographic techniques such as reverse phase high pressure liquid chromatography 
(HPLC), or through size exclusion methods such as dialysis, where appropriate. Following 
purification, inductively coupled plasma mass spectrometry (ICP-MS) is a useful technique for 
assessing residual Cu levels. Fortunately, Cu-free approaches such as SPAAC can be used to avoid 
problems associated with residual Cu. 
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Limiting side reactions with amino acid residues of biomolecules is a necessity to 
maintaining activity in the final conjugate. CuAAC reactions employing the common Cu2+ and 
sodium ascorbate catalyst system are known to lead to the formation of reactive oxygen species, 
which can degrade amino acids such as histidine, arginine, cysteine, and methionine.6 Cu-chelating 
ligands such as THPTA or TBTA and side chain surrogates, such as aminoguanidine (surrogate 
for arginine) can assist in limiting degradation. In addition, cyclooctyne compounds are known to 
react with reduced cysteine residues through a thiol-yne mechanism. However, pre-incubation with 
iodoacetamide has been shown to mitigate this side reaction.6 In order to verify the structure of the 
chemically altered biomolecule, analytical methods such as reverse phase HPLC, LC-MS/MS, and 
peptide mapping can be utilized.111  
The CuAAC and SPAAC reactions have been employed extensively in construction of 
hydrogels due to high yields, mild conditions (aqueous solutions, physiological pH, ambient 
temperature), and minimal formation of byproducts.112-115 An added complication of 
bioconjugation to polymers is the tendency for intra- or inter-molecular entanglement, limiting the 
accessibility to reactive sites. Reduction of this phenomenon can occur through the addition of 
organic solvents known to denature the polymer,6 addition of heat to induce thermal unfolding, or 
altering pH or ionic environment to disrupt specific interactions causing entanglement.116 In other 
cases, limited reactive site availability is due to the viscosity of high MW polymers, requiring more 
dilute reaction conditions. In general, conjugation efficiency will decrease as MW increases due 
to reduced collisions with appropriate geometry and sufficient energy to react, especially for 
polymers such as hyaluronic acid which are self-associating or have secondary structure.117  
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1.9. Lessons Learned from Other Bioconjugation Chemistries: Linker Stability 
Another critical component of bioconjugates is the stability of the linker, since this can also 
have a dramatic impact on the efficacy of the bioconjugate. Both cleavable and non-cleavable 
linker strategies have been used in the ADC field as well as in other bioconjugates. Zimmerman 
and coworkers58 incorporated  the azide UAA p-azidomethyl-L-phenylalanine (pAzF) into 
trastuzumab (Tmab), conjugated via SPAAC chemistry to DBCO-PEG-MMAF. The resultant 
ADCs were highly potent when tested in in vitro cell cytotoxicity assays (Figure 3). The authors 
proposed that their ADCs were released during lysosomal degradation, which has been observed 
in other non-cleavable Tmab-maytansinoid ADCs. Some ADCs with non-cleavable linkers are 
active without cleavage and release of the drug, but the mechanisms of non-cleavable ADCs can 
be more complicated and must be determined experimentally.58, 118-119 Cleavable linkers typically 
exploit environmental factors present in the cellular environment where payload release is desired, 
which involves pH, oxidizing/reducing conditions, or the presence of a relevant enzyme. While 
this approach is attractive in theory, and may be necessary for successful action of the payload, the 
mechanisms that release the payload may not be specific to only the desired target location.120 For 
example, pH-sensitive linkers present in the bioconjugate can encounter acidic microenvironments 
during trafficking to the target location, and could release the payload in unintended locations 
throughout the body, yielding adverse side effects for the patient.120-122 The site of conjugation of 
a payload onto the antibody can affect properties of the ADCs such as stability, immunogenicity, 
antigen binding, and pharmacokinetics. Careful optimization of conjugation site can lead to ADCs 
with desirable properties over ADCs made via random conjugation.59, 123  
Some ADCs suffer from the ‘bystander effect’, which is when the conjugated toxin is 
released from the antibody following internalization in antigen-positive cells, crosses the cellular 
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membrane as a neutral species, and kills surrounding cells that may have lower expression of cell-
surface antigen. In these cases, an understanding of the drug release mechanism is essential. ADC 
may not be sufficient to eliminate all of the solid tumor because cell populations with limited 
surface antigen expression will also be exposed to the toxin.  
Brentuximab vedotin utilizes a cathepsin cleavable linker to conjugate MMAE to the 
antibody, which results in the release of this toxin in a neutral form capable of crossing biological 
membranes of adjacent cells not targeted by the ADC. Conversely, when the structural analogue, 
MMAF, is conjugated to an antibody and released in active form as a charged species, diffusion 
across membranes is limited, and the bystander effect is reduced. Payloads attached using 
cleavable linkers, such as those present in Tmab duocarmazine124 are more prone to the bystander 
effect125 than those containing non-cleavable linkages, such as the thioether linkage in Tmab 
emtansine. This underlines the importance of a thorough understanding of the stability of the linker 
and payload release, since the bystander effect provides an added mechanism to tune therapeutic 
specificity that must be accounted for in the design of ADCs with cleavable linkers. Jain and 
coworkers126-127 have published a more detailed review on ADCs and associated linkers. 
 
1.10. Lessons Learned from Other Bioconjugation Chemistries: Biological Consequence of 
the Linker 
To date, comparative studies focused on the impact of different AAC linkers on 
biodistribution are largely absent from the literature. Fortunately, studies have been conducted 
using alternative bioconjugation chemistries, and the trends for those studies can be extrapolated 
to provide useful insight into the design of bioconjugates that utilize AAC chemistry. Tmab 
emtansine is an ADC used to treat patients with HER2-postitive metastatic breast cancer, and it is 
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composed of an anti-HER2 antibody Tmab linked via a thioether linkage to the maytansinoid DM1 
(Figure 4i).128 The thioether-linked 4i has been reported to be slightly more efficacious in mouse 
models than the disulfide-linked 4ii,120 contrary to other maytansinoid-containing ADCs where the 
disulfide-linked drugs showed greater 
efficacy.98-99, 120, 129 Erickson et al.101 compared 
how the thioether and disulfide linkages in 4i 
and 4ii affected the mechanism of action and 
anticancer activity. In Tmab-sensitive breast 
cancer cell lines, both ADCs showed similar 
potency in terms of cell viability, but in Tmab-
insensitive cell lines, 4i showed slightly greater 
potency than 4ii, although the cause was not 
fully understood. The clearance of 4i in plasma 
(Figure 4B) and in tumor cells (Figure 4C) was 
approximately two-fold slower than 4ii, which 
is most likely a result of improved linker 
stability. The payload delivery to tumors, 
however, was similar for both bioconjugates 
(Figure 4D). While the linker had an impact on 
pharmacokinetics (PK) and the rate of metabolism, both ADCs were successful in payload delivery 
and antitumor activity. Thus, much remains to be learned regarding the implications of linker 
design. 
Figure 4: (A) Parent linker compounds: maleimidomethyl 
cyclohexane-1-carboxylate (MCC) and N-succinimidyl 4-
(2-pyridyldithio)pentanoate (SPP). Tmab-MCC-DM1 (Ai) 
and Tmab-SPP-DM1 (Aii) structures, with DM1 in red, 
linkers in blue, and thioether and disulfide bonds circled. 
(B) Plasma clearance of ADCs, (C) Accumulation of ADCs 
in tumors,  (D) Accumulation of ADC catabolites in 




Efflux pumps, such as multidrug resistance (MDR) proteins, target molecules for export 
out of cells. These pumps are more effective at transporting hydrophobic molecules than 
hydrophilic molecules. In addition, there is a strong correlation between MDR expression and poor 
clinical response.102 Specifically, studies have shown that Tmab linked to DM1 via a hydrophilic 
PEGylated linker is more efficacious towards MDR+ cells than those containing the more 
hydrophobic maleimidomethyl cyclohexane-1-carboxylate (MCC) linker.130 Again, the relative 
hydrophobicity of the linker contributed to differences in activity as well as PK properties of the 
molecules. 
In the context of ADCs, most 
drugs conjugated to the antibody are 
relatively hydrophobic and have minimal 
aqueous solubility, while the antibody 
typically has good aqueous solubility. 
Therefore, the resulting conjugate 
generally has intermediate solubility, 
often proportional to the MW contribution 
of the parent compounds in the overall 
conjugate.  This can provide a significant 
benefit to the drug since hydrophobic drug 
molecules are more likely to enter cells via 
passive diffusion. On the other hand, 
ADCs often exploit the active transport 
mechanisms used to internalize 
Figure 5: (A) Modification of native cysteine residues to 
make homogenous ADCs with DAR of 8, (B) Rank-
order of increasing hydrophobicity of molecules 
conjugated to h1F6 C) Plasma clearance of h1F6 and 
h1F6 ADCs in mice, (D) Determination of 
hydrophobicity using hydrophobic interaction 




antibodies. Therefore, an increase in drug-to-antibody ratios (DAR) of ADCs leads to increased 
potency in vitro, but highly loaded ADCs often suffer from more rapid in vivo clearance.131 
Multiple studies report that by limiting the average DAR to the range of 2-4, potency can be 
maximized without negatively impacting in vivo performance.104, 131-132 Methods have been 
developed to allow for DAR values of up to 8 by utilizing native cysteine residues on human IgG1 
(Figure 5A). Using conventional hydrophobic drug-linker chemistries to make ADCs with a DAR 
of 8 resulted in fast plasma clearance.104, 131-132 Lyon et al.133 reported that by reducing 
hydrophobicity of ADCs through linker design, a DAR of 8 could indeed be achieved without 
accelerating plasma clearance. The authors conjugated 8 MMAF (5v) to an anti-CD70 antibody 
h1F6, using the protease cleavable linker 5iv. PK studies showed faster clearance of the h1F6-5iv 
than the unconjugated h1F6 (Figure 5C). They hypothesized that the difference in clearance maybe 
due to the loss of interchain disulfide bonds, leading to destabilized h1F6. However, the clearance 
of 5i conjugated to h1F6 and unconjugated h1F6 used as a control was similar. Therefore, the 
authors implicated linker hydrophobicity as the cause of accelerated clearance of h1F6-5iv. The 
relative hydrophobicity of h1F6 and conjugates was determined by hydrophobic interaction 
chromatography (HIC), revealing the following trend of increasing hydrophobicity: 
h1F5<5ii<5iii<5iv (Figure 5D). When a modified hydrophilic MMAF version (5ii) was conjugated 
directly to h1F6 with no linker, it had similar hydrophobicity to the parent antibody and both 
showed comparable plasma clearance in vivo. Similar in vitro potency was observed for h1F6-5iv 
and h1F6-5iii, however there was a >4-fold increase in in vivo activity for h1F6-5iii due to slower 
clearance (Figure 5C) of the more hydrophilic h1F6-5iii. Since h1F6-5iii is less hydrophobic than 
h1F6-5iv, it can be suggested that the reduction in hydrophobicity leads to improved plasma 
clearance of ADCs with high DAR of 8. 
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Solubility plays an important role in many physiological processes from biodistribution 
and clearance to immune recognition and response. Insoluble antigens are often processed by 
macrophages, while dendritic cells tend to process soluble materials.1 Therefore, modification of 
the solubility of biomolecules through conjugation can perturb native function, altering 
recognition, trafficking, or uptake events. An understanding of aggregation propensity, with the 
associated decrease in solubility, is of critical importance in protein therapeutics. Aggregated 
proteins have the potential to induce an undesired immune response and lead to potentially serious 
adverse events for the patient.134 In 2014, the FDA issued guidance on immunogenicity assessment 
as a key parameter in the development of therapeutic protein products. Recent studies have also 
shown that anti-drug antibodies formed upon repeat administration of biologic treatments such as 
rituximab have led to an immunogenic response in the patient.135-136 
 
1.11. Utilizing AAC for the synthesis of chemical probes for the development of ASIT 
With the brief overview of autoimmune diseases, their currently understood mechanism, 
and the lack of current viable treatments; ASIT has emerged as a viable strategy for the 
development of novel treatments for autoimmune disease. In this work, AAC library is synthesized 
and utilized for the construction of novel probes and potentially as ASIT for T1D. Both a co-
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CHAPTER 2: DEVELOPMENT OF CHEMICAL BIOLOGY TOOLS FOR PROBING ANTIGEN 
SPECIFIC IMMUNOTHERAPY 
2.1. Introduction 
 The immune system is designed to defend against pathogens and environmental threats. 
Autoimmune diseases develop as a result of the loss of tolerance to self-antigen, leading to an 
improperly functioning immune system that targets its own tissues, organs, and cells.137 Currently 
over 80 autoimmune diseases have been identified, afflicting over 5% of the world’s population.1  
Current clinically available therapies either slow down the progression of autoimmunity or treat 
symptoms associated with the disease. Such therapies suffer from lack of specificity and has led 
to the development of antigen-specific immunotherapy (ASIT) as a potential therapeutic strategy 
for the treatment of autoimmune diseases.138 We have designed a potentially novel ASIT know as 
antigen drug conjugates (AgDCs) to induce tolerance in autoimmune disease. 
 Taking inspiration from antibody drug conjugates (ADC) that have been successful in 
targeted drug delivery to specific receptors in cancer therapy, AgDCs are designed to be an ASIT 
co-delivery system by chemically linking an antigen to a drug for the treatment of autoimmune 
diseases. AgDCs are composed of an antigen (vehicle) which allows for the specific delivery of a 
potent drug (cargo). AgDCs are designed to be conjugated via azide-alkyne chemistry (AAC) for 
facile and rapid construction of different combination of antigens and drugs. Thus, various AgDCs 
can be constructed and used to probe an autoimmune disease animal model for quick and rapid 
identification of the best antigen and drug. In order to construct an AgDC, the following criteria 
must be met: first, a potent drug with easy installation of an AAC handle without compromising 
the drugs potency; second, a known autoantigen of an autoimmune disorder with the corresponding 
animal model that recognized the autoantigen; finally, determining the type of linker that will be 
used to chemically link the drug and antigen (i.e. PEGylated). 
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 In T1D, beta cells that produce insulin are targeted incorrectly by the immune system which 
leads to the decrease and eventual loss in the production of the glucose regulating insulin.14, 139 In 
T1D animal model, non-obese diabetic (NOD) BDC2.5 transgenic mice T cells can recognize the 
peptide sequence known as p79 (AVRPWVRME). Thus, p79 can be used to induce an antigen 
specific immune response in NOD BDC2.5 mice. Another example of an autoimmune disease is 
multiple sclerosis (MS). MS is the most common neurodegenerative disorder believed to be caused 
by an aberrant immune system targeting proteins on the protective nerve covering known as the 
myelin sheath.9 Relapsing-remitting (RR)MS is the most common disease course and is 
characterized by new and increasing symptoms by periods of partial recovery. Experimental 
autoimmune encephalomyelitis (EAE) is an RRMS mouse model where and an adjuvant 
composted of antigenic epitope, PLP139-151 (HSLGKLGHPDKF) with Complete Freud's Adjuvant 
(CFA) can induce disease. Since, the PLP139-151 (PLP) peptide sequence is recognized by antigen-
specific cells, an AgDC with PLP may be able to induce a tolerogenic effect in EAE mice. This 
section is focused on the initial synthesis and optimization of various biological probes (ie. 
fluorophores, AgDCs) for the autoimmune diseases. 
 
2.2. Materials and Methods 
Boronic acid, sodium ascorbate (NaAsc), trimethylamine, rhodamine B, N-
hydroxysuccinimide, 2,4-dihydroxy benzaldehyde, N-acetylglycine, N-terminal 4-pentynoic acid 
and propargyl-N-hydroxysuccinimidyl ester were purchased from Sigma-Aldrich (St. Louis, MO) 
and used as received without further purification. 11-azido-3,6,9-trioxaundecan-1-amine (NH2-
PEG3-N3), Copper (II) sulfate pentahydrate (CuSO4 • 5H2O), and N,N'-dicyclohexylcarbodiimide 
(DCC) were purchased from Acros Organics (Geel, Belgium). Fluorescein 5-Isothiocyanate 
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(isomer I) was obtained from TCI America (Portland, OR).  Propargylglycine functionalized 
peptide pPLP139-151 (p-HSLGKWLGHPDKF-OH) and N-terminal 4-pentynoic acid 
(homopropargyl, hp) modification peptide hpP79 (hp-AVRPWVRME-OH) purchased from 
Biomatik USA, LLC (Wilmington, DE).   
 
2.2.1. Synthetic procedures 
2.2.1.1. Synthesis of Rhodamine B N-hydroxysuccinimide esters (Rhod-NHS ester) 
 
Figure 6: Reaction scheme for the synthesis of Rhod-NHS ester. 
Synthesis of N-(6-(diethylamino)-9-(2-(((2,5-dioxopyrrolidin-1-yl)oxy)carbonyl)phenyl)-
3H-xanthen-3-ylidene)-N-ethylethanaminium (Rhod-B) was adapted from Meng et al.140 Both 
Rhod-B (2.4 g) and N-hydroxysuccinimide were dissolved in 100 mL of  dry acetonitrile, heated 
to 45 °C, and stirred. Then a solution of dicyclohexylcarbodiimide (DCC) (1.2g in 50 mL dry 
acetonitrile) was added slowly to the reaction mixture. The reaction was started at elevated 
temperatures for 1h and then allowed to cool to room temperature for 20 h. Then the white 
precipitate was removed by filtration through Celite® and thefiltrate was concentration on the 
rotary evaporator, then residue was recrystallized in absolute ethanol, filtered and dried to give a 
solid purple product.; 1H NMR (500 MHz, DMSO-d6) δ 8.41 (dd, J = 7.9, 1.2 Hz, 1H), 8.09 (td, J 
= 7.6, 7.6, 7.2 Hz, 1H), 7.97 (td, J = 7.7, 7.7, 1.2 Hz, 1H), 7.67 (dd, J =  7.7, 1.2 Hz, 1H), 7.11 (d, 
J =  2.4 Hz, 1H), 7.08 (d,  J =  2.4 Hz, 1H), 7.03 (s, 1H), 7.00 (s, 1H), 6.97 (d, J = 2.4 Hz, 2H), 
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3.65 (q, J = 7.14, 7.06, 7.06 Hz, 8H), 2.71 (br s, 4H), 2.69-2.65 (m, 2H), 8.44-8.40 (m, 2H), 1.20 
(t, J = 6.99, 6.99 Hz, 12H); MS (TOF ESI+) expected [M+H]+: 541.25 found: 541.25 
 
2.2.1.2. Synthesis of Rhodamine B PEG3 Azide (Rhod-N3) 
 
Figure 7: Reaction scheme for the synthesis of Rhod-N3. 
Synthesis of N-(9-(2-((2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)phenyl)-6-
(diethylamino)-3H-xanthen-3-ylidene)-N-ethylethanaminium (Rhod-N3) was adapted from Meng 
et al.140 To a mixture of Rhod-NHS ester (0.737 mmol) in DMF (20 mL), NH2-PEG3-N3 (6.60 
mmol) in 20 mL H3BO3 buffer (pH = 8.5, 50 mM) was added and stirred at room temperature for 
6 hours. The reaction mixture was frozen and lyophilized to give the crude product as an orange 
liquid. The crude product was dissolved in DMSO and purified by preparative RP-HPLC (Waters 
XBridge C18, 5 µm, 10x250 mm, linear gradient from 5-95% MeCN (+ 0.05% TFA) in H2O (+ 
0.05% TFA) over 20 minutes, detection at 280 nm) to give the final product (57 mg, 18 %) as an 
orange-yellow solid; 1H NMR (500 MHz, DMSO-d6) δ 8.41 (dd, J = 7.9, 1.2 Hz, 1H), 8.09 (td, J 
= 7.6, 7.6, 7.2 Hz, 1H), 7.97 (td, J = 7.7, 7.7, 1.2 Hz, 1H), 7.67 (dd, J =  7.7, 1.2 Hz, 1H), 7.11 (d, 
J =  2.4 Hz, 1H), 7.08 (d,  J =  2.4 Hz, 1H), 7.03 (s, 1H), 7.00 (s, 1H), 6.97 (d, J = 2.4 Hz, 2H), 
3.65 (q, J = 7.14, 7.06, 7.06 Hz, 8H), 2.71 (br s, 4H), 2.69-2.65 (m, 2H), 8.44-8.40 (m, 2H), 1.20 




2.2.1.3. Synthesis of alkyne-modified Pennsylvania Green (Penn Green-Alk) 
 
Figure 8: Reaction scheme for the synthesis of Penn Green-Alk. 
Synthesis of 4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-methyl-N-(prop-2-yn-
1-yl)benzamide (Penn Green-Alk) was adapted from Meng et al.140 To a mixture of Penn Green-
NHS (55.3 µmol) in DMF (0.5 mL), propargylamine (61.2 µmol) in 0.5 mL H3BO3 buffer (pH = 
8.5, 50 mM) was added and stirred at room temperature for 6 hours. The reaction mixture was 
frozen and lyophilized to give the crude product as an orange liquid. The crude product was 
dissolved in DMSO and purified by preparative RP-HPLC (Waters XBridge C18, 5 µm, 10x250 
mm, linear gradient from 5-95% MeCN (+ 0.05% TFA) in H2O (+ 0.05% TFA) over 30 minutes, 
detection at 280 nm) to give the final product (22.5 mg, 84.7%) as an orange-yellow solid; 1H 
NMR (400 MHz, DMSO-d6) δ 7.99 (s, 1H), 7.93-7.87 (m, 1H), 7.40 (d, J = 7.9 Hz, 1H), 6.85 (br 
s, 2H), 6.63 (d, J = 11.2 Hz, 2H), 4.11 (dd, J = 5.6, 2.5 Hz, 2H), 3.17 (t, J = 2.5 Hz, 1H), 2.08 (s, 
3H); HRMS (TOF ESI+) expected [M+Na]+: 442.0867, found: 442.0870. 
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2.2.1.4. Synthesis of Rhodamine B alkyne (Rhod-Alk) 
 
Figure 9: Reaction scheme for the synthesis of Rhod-Alk. 
Synthesis of N-(6-(diethylamino)-9-(2-(prop-2-yn-1-ylcarbamoyl)phenyl)-3H-xanthen-3-
ylidene)-N-ethylethanaminium was adapted from Meng et al.140 To a mixture of Rhod-NHS (0.737 
mmol) in DMF (20 mL), propargylamine (6.60 mmol) in 20 mL H3BO3 buffer (pH = 8.5, 50 mM) 
was added and stirred at room temperature for 6 hours. The reaction mixture was frozen and 
lyophilized to give the crude product as an orange liquid. The crude product was dissolved in 
DMSO and purified by preparative RP-HPLC (Waters XBridge C18, 5 µm, 10x250 mm, linear 
gradient from 5-95% MeCN (+ 0.05% TFA) in H2O (+ 0.05% TFA) over 20 minutes, detection at 
280 nm) to give the final product (120 mg, 49%) as an orange-yellow solid; 1H NMR (500 MHz, 
DMSO-d6) δ 7.82-7.78 (m, 1H), 7.83-7.77 (m, 2H), 7.05-7.00 (m, 1H), 6.42-6.26 (m, 6H), 7.11 (d, 
J =  2.4 Hz, 1H), 7.08 (d,  J =  2.4 Hz, 1H), 7.03 (s, 1H), 7.00 (s, 1H), 6.97 (d, J = 2.4 Hz, 1H), 
3.65 (q, J = 7.14, 7.06, 7.06 Hz, 2H), 3.77 (d, J = 2.5 Hz , 2H), 2.70-2.63 (m, 8H), 2.66 (t, J = 2.5, 




2.2.1.5. Synthesis of 3-Azido-7-hydroxycoumarin (coumarin-N3) 
 
Figure 10: Reaction scheme for the synthesis of coumarin-N3. 
Synthesis of 3-azido-7-hydroxy-2H-chromen-2-one taken from Sivakumar et al.97 A 
mixture of 2,4-dihydroxy benzaldehyde (2.76 g, 20 mmol), N-acetylglycine (2.34 g, 20 mmol), 
anhydrous sodium acetate (60 mmol) in acetic anhydride (100 ml) was refluxed under stirring for 
4 h. The reaction mixture was poured onto ice to give a yellow precipitate. After filtration, the 
yellow solid was washed by ice water before it was refluxed in a solution of conc. HCl and ethanol 
(2:1, 30 mL) for 1 hour, then ice water (40 mL) was added to dilute the solution. The solution was 
then cooled in an ice bath and NaNO2 (40 mmol) was added. The mixture was stirred for 5-10 
minutes and NaN3 (60 mmol) was added in portions. After stirring for another 15 minutes, the 
resulting precipitate was filtered off, washed with water, and dried under reduced pressure to afford 
a brown solid; 720 mg (18% overall yield). The product was pure enough for further reactions. 1H 
NMR (DMSO-d6, 500 MHz) δ 6.77 (d, J = 2.2 Hz, 1 H), 6.82 (dd, J = 8.5, 2.2 Hz, 
1 H), 7.47 (d, J 




2.2.1.6. Synthesis of Fluorescein thiourea alkyne (FTU-Alk) 
 
Figure 11: Reaction scheme for the synthesis of FTU-Alk. 
Synthesis of 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-(3-(prop-2-yn-1-yl)thioureido) 
benzoic acid (fluorescein thiourea alkyne; FTU-Alk; FTUA) was adapted from Meng et al.140 To 
a mixture of FITC (200mg, 511.4 µmol) and 1-amino-11-azido-3,6,9-trioxa-undecane (131mg, 
119.09 μL, 0.616 mmol) in DMSO (1 mL) was added triethylamine (75 μL, 0.514 mmol), and the 
mixture was stirred for 2 h at room temperature in the dark. The reaction mixture was then frozen 
at -20°C and lyophilized to afford a red oil. The crude product was dissolved in DMSO and purified 
by preparative RP-HPLC (Waters XBridge C18, 5 µm, 10x250 mm, linear gradient from 5-95% 
MeCN (+ 0.05% TFA) in H2O (+ 0.05% TFA) over 20 minutes, detection at 280 nm) to give the 
final product (176.5 mg, 77%) as an red-oil; 1H NMR (500 MHz, DMSO-d6) δ 7.82-7.78 (m, 1H), 
7.83-7.77 (m, 2H), 7.05-7.00 (m, 1H), 6.42-6.26 (m, 6H), 7.11 (d, J =  2.4 Hz, 1H), 7.08 (d,  J =  
2.4 Hz, 1H), 7.03 (s, 1H), 7.00 (s, 1H), 6.97 (d, J = 2.4 Hz, 1H), 3.65 (q, J = 7.14, 7.06, 7.06 Hz, 
2H), 3.77 (d, J = 2.5 Hz , 2H), 2.70-2.63 (m, 8H), 2.66 (t, J = 2.5, 2.5 Hz, 1H)1.08 (t, J = 6.95, 
6.95 Hz, 12H); HRMS expected [M+H]+: 445.0853, found: 445.0858. 
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2.2.1.7. Synthesis of Fluorescein thiourea azide FTU-N3 
 
Figure 12: Reaction scheme for the synthesis of FTU-N3 
Synthesis of 5-(3-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)thioureido)-2-(6-hydroxy-
3-oxo-3H-xanthen-9-yl)benzoic acid (fluorescein thiourea azide; FTU-N3) was adapted from 
Meng et al.140 To a mixture of FITC (200 mg, 511.4 µmol) and NH2-PEG3-N3 (33.92 mg, 0.616 
mmol) in DMSO (1 mL) was added triethylamine (75 μL, 0.514 mmol), and the mixture was stirred 
for 2 h at room temperature in the dark. The reaction mixture was then frozen at -20 °C and 
lyophilized to afford a red-orange powder. The crude product was dissolved in DMSO and purified 
by preparative RP-HPLC (Waters XBridge C18, 5 µm, 10x250 mm, linear gradient from 5-95% 
MeCN (+ 0.05% TFA) in H2O (+ 0.05% TFA) over 20 minutes, detection at 280 nm) to give the 
final product (210.01 mg, 67%) as an orange-yellow solid; 1H NMR (500 MHz, DMSO-d6) δ 8.41 
(s, 1H), 8.08 (s, 1H), 7.74 (d, J = 8.38 Hz, 1H), 7.18 (d, J =  8.0 Hz, 1H), 6.67 (d, J =  2.2 Hz, 2H), 




2.2.1.8. Synthesis of Dexamethsone-azide (Dex-N3) 
 
Figure 13: Reaction scheme for the synthesis of Dex-N3 
Dexamethasone (300 mg, 746.39 µmol) was added to a flame dried 250 mL round bottom 
flask with a stir bar and septa. Anhydrous MeCN (60 mL) was added under nitrogen, then DIPEA 
(720 µL, 3821.95 µmol) via glass syringe. The flask was stirred for 10 min before azidoacetic acid 
NHS ester (757.28 mg, 3821.95 µmol) was added as a powder. The reaction mixture was stirred 
overnight at room temperature before being analyzed by HPLC. Additional equimolar aliquots of 
azidoacetic acid NHS ester were added, followed by stirring for 2 hours at room temperature and 
analyzing by HPLC, until no additional benefit was observed. The crude reaction mixture was 
evaporated under reduced pressure, then dissolved in 4:6 MeCN:H2O and purified by prep HPLC. 
The resulting column fractions were evaporated under reduced pressure to yield the final product 
as a white powder. 1H NMR (500 MHz, DMSO-d6) δ 7.30 (d, J = 10.2 Hz, 1H), 6.23 (dd, J = 10.1, 
1.9 Hz, 1H), 6.01 (t, J = 1.7 Hz, 1H), 5.45 (dd, J = 5.0, 1.4 Hz, 1H), 5.23 (s, 1H), 5.17 (d, J = 17.5 
Hz, 1H), 4.90 (d, J = 17.6 Hz, 1H), 4.32 – 4.19 (m, 2H), 4.19 – 4.11 (m, 1H), 2.88 (dqd, J = 11.5, 
7.2, 4.1 Hz, 1H), 2.62 (tdd, J = 13.6, 6.0, 1.7 Hz, 1H), 2.44 – 2.32 (m, 1H), 2.35 – 2.28 (m, 1H), 
2.22 – 2.05 (m, 3H), 1.77 (dt, J = 11.2, 5.2 Hz, 1H), 1.70 – 1.58 (m, 1H), 1.56 (dd, J = 13.8, 2.0 
Hz, 1H), 1.49 (s, 3H), 1.35 (qd, J = 12.9, 5.0 Hz, 1H), 1.08 (ddd, J = 12.1, 8.2, 4.1 Hz, 1H), 0.89 
(s, 3H), 0.80 (d, J = 7.2 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 204.36, 185.30, 168.28, 
167.10, 152.77, 129.03, 124.12, 102.00, 100.61, 90.52, 70.63, 70.34, 69.00, 49.34, 48.09, 48.05, 
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47.87, 43.33, 35.69, 35.53, 33.67, 33.51, 31.92, 30.28, 27.32, 23.03, 22.98, 16.31, 15.15, 1.19. 
Expected [M+H]+ = 476.2191 Da; Observed [M+H]+ = 476.2067 Da. 
 
2.2.1.9. Synthesis of Fluorescein Rhod –p79 
 
Figure 14: Reaction scheme for the synthesis of Rhod-p79. 
To a solution of p79-Alk (28 μmol) in 37.5 mL deionized H2O was added Fluorescein 
thiourea azide (42.82 μmol, 1.5 eq.) in 5.642 mL DMF, while protecting the reaction from light. 
Then 4,350 μL of a premixed solution of CuSO4•5H2O (7.25 μmol) and 
Tris(benzyltriazolylmethyl)amine (THPTA; 62.9 μmol) in deionized H2O was added to the 
reaction mixture, followed by 3200 μL of aminoguanidine•hydrochloride (578.0 μmol) in 
deionized H2O. The reaction was allowed to stir at 40° C for 1-2 min before a 100 uL aliquot was 
removed for analytical HPLC to monitor reaction progress at 40° C. Then 5725 μL of NaAsc 
(578.0 μmol) in deionized H2O was added to the reaction mixture. After 24 hours the reaction 
appears to no longer progress via HPLC analysis, the reaction mixture was purified by preparative 
HPLC on a Waters XBridge BEH C18, 5 μm, 130 Å, 19x250 mm column using a gradient of MeCN 
in H2O (constant 0.05% TFA). The isolated fractions were evaporated under reduced pressure to 
remove residual MeCN, then frozen at -20°C and lyophilized to yield a light pink oil. MS (TOF 
ESI+) expected [M+2H]3+ = 656.9668 Da; Observed [M+2H]3+ = 665.2963 Da 
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2.2.1.10. Synthesis of Dex-p79. 
 
Figure 15: Reaction scheme for the synthesis of Dex-p79. 
To a solution of p79-Alk (28 μmol) in 37.5 mL deionized H2O was added Dexamethasone 
azide (42.0 μmol, 1.5 eq.) in 5.642 mL DMF. Then 4,350 μL of a premixed solution of 
CuSO4•5H2O (7.25 μmol) and THPTA (62.9 μmol) in deionized H2O was added to the reaction 
mixture, followed by 3200 μL of aminoguanidine•hydrochloride (578.0 μmol) in deionized H2O. 
The reaction was allowed to stir at 40° C for 1-2 min before a 100 uL aliquot was removed for 
analytical HPLC to monitor reaction progress 40° C. Then 5725 μL of NaAsc (578.0 μmol) in 
deionized H2O was added to the reaction mixture. After 2 hours the reaction appeared to be 
complete via HPLC analysis, the reaction mixture was purified by preparative HPLC on a Waters 
XBridge BEH C18, 5 μm, 130 Å, 19x250 mm column using a gradient of MeCN in H2O (constant 
0.05% TFA). The isolated fractions were evaporated under reduced pressure to remove residual 
MeCN, then frozen at -20°C and lyophilized to yield a light brown powder. MS (TOF ESI+) 
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expected [M+H]+ = 1812.94 Da, [M+2H]2+ = 906.4 Da; Observed [M+H]+ = 1812.8748 Da., 
Observed [M+2H]2+ = 906.4775 Da. 
2.2.2. Analytical characterization 
NMR spectra were collected on a Bruker Avance AVIII 500 MHz spectrometer equipped with a 
dual carbon/proton cryoprobe, and all samples were dissolved in 600 μL of D2O or DMSO-d6. 
Data processing was completed using MestReNova 11.0 (Santiago de Compostela, Spain). 
LC/MS sample analysis was completed on a Waters Xevo G2, employing linear elution 
gradients of 15-100% acetonitrile in water (constant 0.1% formic acid) over 45 min, on a Waters 
XBridge BEH C18, 1.7 μm, 130 Å stationary phase (0.075 x 250 mm), with a 0.5 μL/min flow rate 
and 50°C column temperature. Electrospray ionization, operating in the positive mode (ESI+), was 
used as the ionization source with a QTof mass analyzer used for detection. 
All HPLC chromatographic analysis was conducted on a Waters Alliance HPLC system 
equipped with either a diode array detector or dual wavelength UV/Vis detector. For RP-HPLC, 
general chromatographic conditions employed a linear elution gradient from 5-95% acetonitrile in 
water (constant 0.05% trifluoroacetic acid) over 50 min, on a Waters XBridge BEH C18, 3.5 μm, 
130 Å stationary phase (4.6 x 150 mm), with a 1.0 mL/min flow rate and a 35°C column 
temperature. For semi-preparative HPLC, a linear elution gradient of acetonitrile in water (constant 
0.05% trifluoroacetic acid) over 20 min, on a Waters XBridge BEH C18, 5 μm, 130 Å stationary 
phase (19 x 250 mm), with a 14.0 mL/min flow rate. Gradients were optimized for each run using 
the identical stationary phase in a 4.6 x 250 mm configuration. 
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2.3. Results and Discussion 
2.3.1. Design and Rationale behind AgDCs 
AgDCs were designed to selectively deliver a drug payload molecule which is chemically 
linked to an antigen-directing vehicle to antigen-specific cells. The selected drug must have the 
following qualities: high potency, known mechanism of action (MOA), and an available synthetic 
handle. These characteristics allow us to install an AAC handle at a position of the drug without 
losing potency. Dexamethasone (Dex) was chosen as our drug molecule because it meets all the 
required qualities to be used in AgDCs, and it has successfully been used in ADCs in literature.141 
For both PLP and p79, the C-terminus is required for immunological recognition, thus, the N-
terminus was chosen as the site of AAC installation via the final step of solid-phase peptide 
synthesis preceding cleavage from the resin. By conjugating PLP or p79 to Dex, we expect a 
reduced inflammatory response in their respective autoimmune disease models. However, the 
focused of this section is to optimize AAC chemistry for the facile bioconjugation of a peptide to 
a drug. Finally, the linker that chemically connects the antigen and drug must be taken into 
consideration, specifically the following: linker flexibility, length, and stability. Long linkers may 
affect internalization of AgDCs into the immune cell, while a short linker may hinder binding to 
the cell surface. Thus, we employed a moderate length linker with the ability to be hydrolyzed in 
the cell to specifically release the potent drug. 
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2.3.2. Synthesis of chemical biology components for CuAAC reactions 
For the facile and rapid construction of chemical biology probes we selected copper-
catalyzed azide-alkyne cycloaddition (CuAAC) chemistry to be utilized in the final step in the 
synthesis of bioconjugates. CuAAC chemistry was selected because of its wealth in literature 
optimization142-145 and its extensive use in bioconjugation145-150. Specifically, CuAAC reactions 
(Figure 16A) are known to be high yielding, produce benign side products, use mild reaction 
conditions, and are highly selective. Various small molecules and peptides with alkyne or azide 
handles were synthetized and utilized to make either AgDCs or other immunology active 
molecules in future chapters. (Figure 16B-D).  
Azide or alkyne handles were installed via three types of chemistry: N-
hydroxysuccinimidyl activated esters (NHS ester) with corresponding nucleophile (primary 





Figure 16: Chemical probes (A) Generic reaction scheme for a copper-catalyzed azide-alkyne 
cycloaddition. (B) Selected Drug Dexamethasone (Dex) for AgDCs. (C) N-termini modified antigens 
for AgDCs. D) Fluorophores with azide or alkyne handles for tracking bioconjugates. 
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and during solid-phase peptide synthesis by utilizing Hexafluorophosphate Azabenzotriazole 
Tetramethyl Uronium (HATU) to activate the carboxylic acid on 4-pentynoic acid for the 
installation of an alkyne handle on the N-terminus of PLP. The following section will discuss 
unique challenges faced when we first attempted to synthesize our bioconjugates and our final 
CuAAC optimization. 
 
2.3.3. Optimization of CuAAC reactions for modified PLP and p79 
Initial work in our group was focused on optimizing the CuAAC reaction between 
purchased propargylglycine-PLP (pPLP) and coumarin-N3. Method development proved 
unsuccessful in ‘clicking’ pPLP to coumarin-N3. In order to determine why the reaction did not 
proceed under various conditions, we chose to use a simpler alkyne substrate. Propargylglycine 
was selected as a substrate because it was the simplest reactive component in pPLP. 
Propargylglycine was also unsuccessful in conjugating to Dex-N3 when stoichiometric or sub-
stoichiometric copper was used. While it was not clear at the time why both pPLP and 
propargylglycine failed to conjugate to coumarin-N3 (Table 2), we chose to simplify the CuAAC 
system even further and use propargylamine as a substrate.  
Upon running the CuAAC reaction with propargylamine and couarmin-N3, the reaction 
proceeded in less than 30 min at room temperature. The product was verified via 1H NMR by 
identification of the unique resonance for the triazole proton (not shown). This result pointed 
toward a problem with the primary amine on both of the failed substrates. Significant literature 
presence exists for utilizing amines as ligands for copper. We hypothesized that the primary amine 
in propargylglycine chelated to copper and rendered the catalyst inactive. To test this hypothesis, 
we ran the reaction with super-stoichiometric copper to ensure available copper for the CuAAC 
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reaction to conjugate propargylglycine to coumarin azide. This method resulted in detectable 
product formation verified via 1H NMR (not shown). To further test our hypothesis, we Boc-
protected pPLP to make Boc-PLP, which was successful in conjugating to coumarin-N3 via 
CuAAC chemistry. In order to avoid having to protect and deprotect pPLP, we decided to change 
our design of our PLP to not include a free primary amine near the alkyne handle. We decided to 
incorporate a homopropargyl handle on the N-terminus of PLP (hpPLP).  
To determine if having a homopropargyl handle on the N-terminus would be feasible for 
CuAAC, we first tested if 4-pentynoic acid linker would conjugated to coumarin-N3. To our 
delight, the reaction proceeded to form the triazole product. A new peptide was synthesized via 
solid-phase peptide synthesis to produce the homopropargyl-PLP (see analytical characterization). 
The CuAAC reaction between hpPLP and coumarin-N3 proceeded with no major method 
development. With successful new design, the material was given to a fellow graduate student to 
synthesized AgDCs. The stark difference between pPLP and hpPLP may also be due to pPLP’s 
primary amine and histidine nitrogen chelating to copper and thus inhibiting the CuAAC reaction. 
Table 2. Summary of failed and successful CuAAC reactions 
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The focus this work turned towards synthesizing T1D AgDCs by successfully conjugation 
homopropargyl-p79 (hpP79) to coumarin-N3, Rhod-N3, and Dex-N3. 
Optimization of CuAAC reactions were predominately done in aqueous media, however, 
when conjugating to less soluble organic compounds, the assistance of organic solvents (i.e. 
DMSO, EtOH, DMF) was used. Other components tested during the optimization of CuAAC 
reactions included balancing catalytic loading (Cu), using the stabilizing ligand THPTA, including 
aminoguanidine to help prevent the oxidation of methionine in p79, varying stoichiometric ratio 
to produce high yields, testing with elevated temperature. HPLC analysis proved to be the most 
useful technique in method development and product analysis due to the distinct hydrophobicity 
of starting materials and products. 
 
2.3.4. Analytical Characterization 
Synthesized molecules were characterized using various analytical technique such as, 
HPLC, NMR, LC/MS and other spectroscopic techniques. Small molecule (fluorophores and Dex-
N3) characterization (
1HNMR/MS) were straight forward and the data can be found in the material 
and methods section. The molecular heterogeneity of peptide containing material (PLP, Dex-p79, 
Rhod-p79) required additional characterization (HPLC; HSQC; LC/MS; LC/MSMS).  HPLC 
analysis with UV/VIS detection of purified hpPLP provided purity values >96% (Figure 17). 
Analysis by LC/MS detection multiple charge state verified the synthesis of hpPLP (Figure 14) 
and LC/MS/MS was used to verify peptide sequence and modification (not shown). LC/MS 
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analysis for both purified AgDC Dex-p79 and purified Rhod-p79 detected multiple charge states 
that suggest the successful attachment 
of peptide antigen. 1H/13C 
heteronuclear single quantum 
coherence (HSQC) NMR was used as 
a qualitative analysis technique to 
verify successful bioconjugation of 
hpP79 and Dex-N3.  The resonance 
corresponding to the alkyne linker on the modified peptide (Figure 19A; δ(1H) ≈ 2.6 ppm, δ(13C) 
≈ 70 ppm) is in a unique chemical environment and separated from other signals. Upon 
conjugation, the resonance shifts downfield upon successfully ‘clicking” to Dex and being 
incorporated into the triazole ring (Figure 19B). With Dex-p79 in hand the next step would be to 
check whether our AgDC will have an immunological effect.  
Figure 17: HPLC chromatogram showing single peak for purified 
hpPLP via an xBridge C18 5um (4.6X250mm) gradient 5:95 to 
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Here we presented the successful synthesis of several azide/alkyne containing small 
molecules and peptides as well at the optimization of CuAAC chemistry for our purposes. For the 
installation of azide/alkyne handles, we utilized various synthetic techniques such as NHS 
chemistry, isothiocyanate chemistry, and solid-phase peptide synthesis. CuAAC optimization 
reviled our initial substrate pPLP may have been chelating copper and thus inhibiting the reaction. 
By redesigning our modified peptides to incorporate a homopropargyl linker, synthesis of various 
bioconjugates have been successful. All future work in our group has focused on utilizing a 
homopropargyl linker on peptides or proteins when trying to use CuAAC chemistry to construct 
bioconjugates. Our AgDCs for T1D need to be tested in vitro to determine if specificity has been 
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CHAPTER 3: SOLUBLE ANTIGEN ARRAYS DISPLAYING A MULTIVALENT MIMOTOPES FOR 
THE TREATMENT OF TYPE 1 DIABETES 
3.1. Introduction 
Type 1 diabetes (T1D) is an autoimmune disease that affects 2 in 1000 children and young 
adults.139 It is an aggressive and devastating form of diabetes caused by an aberrant immune 
response resulting in the destruction of insulin-producing beta cells in the pancreas. The cause for 
the development of T1D is still unknown but a combination of genetic and environmental factors 
increase the susceptibility of developing the disease.139, 151 Advancements over the last few 
decades have led to new diagnostics tools, novel therapies for managing the disease, and the 
discovery of causative antigens. Recent research has aimed to deliver antigens in a format that 
induces antigen-specific tolerance.28, 38 Peptide-based approaches are more selective than protein-
based therapies for delivery of specific epitopes including mimotopes, which target T cells clones 
for which the natural epitope is not known or for which the known epitope is recognized with poor 
affinity. However, a drawback of the administration of peptides in vivo is their rapid diffusion and 
dilution, which may result in insufficient uptake on a per cell basis.  
Many current approaches to antigen-specific immunotherapy (ASIT) exhibit 
characteristics similar to traditional vaccines. Vaccines are typically particulate and designed to 
initiate a directed adaptive immune response to specific antigens in order to provide a robust 
“protective” immunological response upon re-challenge. Conversely, allergy shot therapies use 
soluble allergens to hyposensitize the immune response and establish tolerance.152 This is typically 
accomplished by delivering low doses of soluble antigens via subcutaneous injection over an 
extended period of time. Allergen-specific immunotherapies are known to hyposensitize immune 
responses, thus providing a benchmark for design of ASIT delivery systems for autoimmune 
diseases that has yet to be explored.153 
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Scheme 1. Synthesis of SAgA and cSAgA Components and Molecules: (A) Alkyne-Functionalization of fluorescein 
isothiocyanate; (B) structures of homopropargyl-modified peptide and aminooxy-modified peptide; (C) hydrolyzable 
Soluble Antigen Array (SAgA); (D) “click” Soluble Antigen Array (cSAgA)  
 
SAgAs have been designed to bundle peptides together for more efficient uptake in vivo 
and, in some cases, achieve multivalent engagement of B cells.64, 154 In addition, SAgAs uptake 
results in epitope presentation to targeted T cells in the absence of costimulation or 
proinflammatory cytokines, which may induce antigen-specific immune tolerance as a way to treat 
T1D. SAgAs are constructed using a hydrophilic linear polymer, hyaluronic acid (HA), grafted 






nanoparticles, dendrimers) which are innately more ridged with fixed spacing and positioning of 
ligands, SAgAs are capable of contouring the receptor spacing on the cell surface. Thus, SAgAs 
are able to engage cell surface receptors with “high avidity multivalent antigen” by the molecules 
high conformational flexibility to allow for greater interactions with the cell surface to bind and 
cluster receptors.155-162 We have previously reported utilizing soluble antigen arrays (SAgAPLP) 
constructed by conjugating multiple repeating copies of autoantigen proteolipid protein peptide 
(PLP139-151) to HA to induce tolerance in a multiple sclerosis (MS) mouse model known as 
experimental autoimmune encephalomyelitis (EAE). Both the hydrolyzable linked molecule 
SAgAPLP and non-hydrolyzable “clicked” molecule cSAgAPLP were able to cause B cell anergy, 
which was induced by BCR engagement and clustering in in vitro studies; as well as, the complete 
suppression of EAE disease symptoms compared to the control group results in in vivo studies. 
cSAgAPLP showed enhanced efficacy when compared to SAgAPLP, possibly due the stable covalent 
linkage in cSAgAPLP.
64, 163-169 
While the immune response of MS is distinct from T1D, the mechanism of SAgAs is a 
novel strategy for the delivery of autoantigen. Here, we reported tailoring our SAgA technology 
as a therapeutic for another autoimmune diabetes, T1D. We synthesized two versions of SAgAs 
composed of HA polymer backbone with multiple repeating copies of the T1D autoantigen 
mimotope p79 (AVRPLWVRME) employing either a degradable or covalent linker. The p79 
mimotope presented on the I-Ag7 MHC class II of non-obese diabetic (NOD) mice is recognized 
by CD4+ T cells from BDC2.5 T cell receptor (TCR) transgenic mice.170 These T cells have been 
identified as islet-infiltrating T cells171 and shown to also respond to the WE14 peptide from ChgA 
that has been modified by transglutaminase172 and to hybrid insulin peptides resulting from the 
fusion of insulin C peptide and WE14 (aka 2.5HIP).173 These T cells are pathogenic and rapidly 
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transfer disease when transferred as activated cells in NOD mice or as naïve T cells in NOD.SCID 
mice.174-175 The bioconjugates were constructed via aminooxy chemistry (hydrolyzable: SAgAp79) 
or copper-catalyzed alkyne-azide cycloaddition (CuAAC) chemistry (non-hydrolyzable: 
cSAgAp79). Our ASIT technology was characterized via various analytical techniques: high-
performance liquid chromatography (HPLC), nuclear magnetic resonance spectroscopy (NMR), 
circular dichroism (CD), dynamic light scattering (DLS), and fluorescence. The specificity and 
efficiency of T cell stimulation by these SAgAs was demonstrated by in vitro treatment of 
splenocytes from BDC2.5 versus NOD mice, and we identified conventional dendritic cells (cDCs) 
as the most efficient type of antigen-presenting cells (APCs) responsible for the presentation of 
SAgA-derived epitopes to T cells. We also observed that cSAgAp79 are more stimulatory than 
SAgAp79, a property that appears to be more associated with the N-terminal peptide modification 
than their peptide release properties. In summary, our results show that SAgA containing multiple 
copies of P79 can induce potent antigen-specific diabetogenic T cell responses in in vitro 
autoimmune diabetes models. 
 
3.2. Materials and Methods 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), 2-(N-
morpholino)ethane-sulfonic acid sodium salt (MES), tris(3-hydroxypropyltriazolylmethyl)amine, 
sodium ascorbate (NaAsc), and Propargyl-N-hydroxysuccinimidyl ester were purchased from 
Sigma-Aldrich (St. Louis, MO) and used as received without further purification. Hyaluronic acid 
sodium salt (MW 16 kDa) was purchased from Lifecore Biomedical (Chaska, MN). 11-azido-
3,6,9-trioxaundecan-1-amine (NH2-PEG3-N3), N-hydroxysuccinimide, Copper (II) sulfate 
pentahydrate (CuSO4 • 5H2O) was purchased from Acros Organics (Geel, Belgium). Alkyne-
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functionalized peptide bearing an N-terminal 4-pentynoic acid (homopropargyl, hp) modification, 
hpP79 (hp-AVRPLWVRME-OH), aoP79 (aminooxy-AVRPLWVRME-OH) and an 
immunologically killed version (with two permuted amino acids) AVPRLWVRME (P79k) were 
obtained from Biomatik USA, LLC (Wilmington, DE). 
 
3.2.1. Synthesis and Labeling of Soluble Antigen Arrays 
Hydrolyzable SAgAp79 and its fluorescein isothiocyanate (FITC)-labeled version 
(fSAgAp79), non-hydrolyzable cSAgAp79 and its fluorescein thiourea-labeled (fcSAgAp79) were 
synthesized and characterized as previously reported. Peptide conjugation was determined through 
gradient reverse-phase analytical high-performance liquid chromatography (RP-HPLC). 
 
Synthetic Procedures 
3.2.1.1. Synthesis of Fluorescein thiourea alkyne (FTUA) 
Synthesis of 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-(3-(prop-2-yn-1-yl)thioureido) 
benzoic acid (fluorescein thiourea alkyne; FTUA; Scheme 1A) was adapted from Meng et al.140 
Triethylamine (75 μL, 0.514 mmol) was added to a mixture of FTUA (200mg, 511.4 µmol) and 
1-amino-11-azido-3,6,9-trioxa-undecane (131mg, 119.09 μL, 0.616 mmol) in DMSO (1 mL) and 
the mixture was stirred for 2 h at room temperature in the dark. The reaction mixture was then 
frozen at -20°C and lyophilized to afford a red oil. The crude product was dissolved in DMSO and 
purified by preparative RP-HPLC (Waters XBridge C18, 5 µm, 10x250 mm, linear gradient from 
5-95% MeCN (+ 0.05% TFA) in H2O (+ 0.05% TFA) over 20 minutes, detection at 280 nm) to 
give the final product (176.5 mg, 7%) as an orange-yellow powder; 1H NMR (500 MHz, DMSO-
d6) δ 7.82-7.78 (m, 1H), 7.83-7.77 (m, 2H), 7.05-7.00 (m, 1H), 6.42-6.26 (m, 6H), 7.11 (d, J =  2.4 
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Hz, 1H), 7.08 (d,  J =  2.4 Hz, 1H), 7.03 (s, 1H), 7.00 (s, 1H), 6.97 (d, J = 2.4 Hz, 1H), 3.65 (q, J 
= 7.14, 7.06, 7.06 Hz, 2H), 3.77 (d, J = 2.5 Hz , 2H), 2.70-2.63 (m, 8H), 2.66 (t, J = 2.5, 2.5 Hz, 
1H)1.08 (t, J = 6.95, 6.95 Hz, 12H): HRMS expected [M+H]+: 445.0853, found: 445.0858. 
 
3.2.1.2. Synthesis of azide-functionalized hyaluronic acid (HA-N3) 
Synthesis of HA-N3 (Scheme 1A) was adapted from Hu et al and Di Meo et al.
115, 140 
Sodium hyaluronate (93.9 μmol, 16 kDa average MW) was added to a 250 mL round bottom flask 
with stir bar, followed by 100 mL of 50 mM MES buffer (pH = 4.0). The mixture was stirred until 
in solution (~15 minutes) before EDC (23.1 mmol) was added neat, then N-hydroxysuccinimide 
(18.8 mmol) added neat. The mixture was stirred for 5 minutes before H2N-PEG3-N3 (4.51 mmol) 
in 20 mL MES buffer was added. The solution was then stirred for 24 hours at room temperature 
before being dialyzed in 6-8 kDa cutoff dialysis tubing against 4.5 L of 1.0 M NaCl solution for 
24 hours, then 4.5 L of deionized water (4 x 12 hours). The volume in the bag was then transferred 
to vials, frozen, and lyophilized to yield a white powder (1.61 g, 95.0%).  
 
3.2.1.3.  Synthesis of Non-Hydrolyzable Soluble Antigen Arrays (cSAgAs p79) 
HA-N3 (1.6 μmol) was added as a 30 μM solution in phosphate buffer (pH= 7.0) to a 250 
mL round bottom flask with stir bar. Then hpP79 (40 μmol) was then added as a 3.52 mM solution 
in phosphate buffer (pH= 7.0), followed by a premixed solution of THPTA (70 μmol) and CuSO4 
• 5H2O (14.5 μmol) in phosphate buffer (pH= 7.0). The solution was allowed to stir for 1-2 minutes 
before a 100 μL aliquot was removed for HPLC analysis. NaAsc (295 μmol) was then added to 
the reaction mixture as a 100 mM solution phosphate buffer (pH= 7.0). The reaction was allowed 
to 24 hours at room temperature. Additional 100 μL aliquots were removed throughout the course 
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of the reaction to determine the extent of conjugation. Then the reaction solution was quenched by 
adding 0.5 mL of 50 mM EDTA, then transferred to 6-8 kDa dialysis tubing and dialyzed against 
4.5 L of 1.0 M NaCl (3 x 8 hours), then 4.5 L of deionized H2O (6 x 8 hours). The volume in the 
bag was then transferred to vials, frozen, and lyophilized. 
 
3.2.1.4. Synthesis of Non-Hydrolyzable Fluorescent Soluble Antigen Arrays (fcSAgAs p79) 
HA-N3 (2.0 μmol) was added as a 30 μM solution in phosphate buffer (pH= 7.0) to a 250 
mL round bottom flask with stir bar. Then hpP79 (40 μmol) was then added as a 3.52 mM solution 
in phosphate buffer (pH= 7.0), followed by fluorescein thiourea alkyne (4 μmol), and then by a 
premixed solution of THPTA (70 μmol) and CuSO4 • 5H2O (14.5 μmol) in phosphate buffer (pH= 
7.0). The solution was allowed to stir for 1-2 minutes before a 100 μL aliquot was removed for 
HPLC analysis. NaAsc (295 μmol) was then added to the reaction mixture as a 100 mM solution 
phosphate buffer (pH= 7.0). The reaction was allowed to 24 hours at room temperature. Additional 
100 μL aliquots were removed throughout the course of the reaction to determine the extent of 
conjugation. Then the reaction solution was quenched by adding 0.5 mL of 50mM EDTA, then 
transferred to 6-8 kDa dialysis tubing and dialyzed against 4.5 L of 1.0 M NaCl (3 x 8 hours), then 
4.5 L of deionized H2O (6 x 8 hours). The volume in the bag was then transferred to vials, frozen, 
and lyophilized. 
 
3.2.1.5. Hydrolyzable Soluble Antigen Arrays (SAgAp79; k)  
Single-step grafting of aminooxy peptides to 16 kDa HA was performed as described 
previously.168 Briefly, HA was dissolved in 20 mM acetate-buffered solution (pH 5.5 ± 0.1) and 
aminooxy reactive peptide was added simultaneously. After addition of the peptides, the reaction 
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solution was adjusted to pH 5.5 ± 0.1 and stirred at 500 rpm using a magnetic stir bar for 16 h at 
room temperature. The samples were then transferred to dialysis bags (MWCO 6000-8000 Da, 
Spectrum Laboratories, Inc., Rancho Dominguez, CA) and dialyzed against 2 L of deionized water 
for 24 h, with dialysis water exchanged every 6 h to remove unreacted peptides and residual buffer. 
After dialysis, the dialysate was frozen at −70°C and lyophilized. 
 
3.2.1.6. Hydrolyzable Fluorescent Soluble Antigen Arrays (fSAgAp79) 
Single-step grafting of aminooxy peptides to 16 kDa HA was performed as described 
previously.168 Briefly, HA was dissolved in 20 mM acetate-buffered solution (pH 5.5 ± 0.1) and 
aminooxy reactive peptide and FITC were added simultaneously. After addition of the peptides, 
the reaction solution was adjusted to pH 5.5 ± 0.1 and stirred at 500 rpm using a magnetic stir bar 
for 16 h at room temperature. The samples were then transferred to dialysis bags (MWCO 6000-
8000 Da, Spectrum Laboratories, Inc., Rancho Dominguez, CA) and dialyzed against 2 L of 
deionized water for 24 h, with dialysis water exchanged every 6 h to remove unreacted peptides 
and residual buffer. After dialysis, the dialysate was frozen at −70°C and lyophilized. 
 
3.2.2. Analytical Characterization of Soluble Antigen Arrays 
NMR spectra were collected on a Bruker Avance AVIII 500 MHz spectrometer equipped 
with a dual carbon/proton cryoprobe, all samples were dissolved in 600 μL of D2O for 
examination.  MestReNova 11.0 was used for NMR data analysis.  
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RP-HPLC analysis was done using a Waters Alliance HPLC system equipped with either 
a dual wavelength UV/Vis detector or diode array detector. For the quantitative determination of 










)             Equation 1 
where Ncon = number of conjugated peptides per backbone, npep = moles of peptide used in reaction, 
nHA = moles of HA-N3 used in reaction, Vpre = total reaction volume before NaAsc is added, Vsam 
= volume of “pre-NaAsc” sample removed from reaction mixture, PAt = measured peak area of 
peptide at time t, PAstart = measured peak area of free peptide before NaAsc is added to the reaction. 
General chromatographic conditions employed a Waters XBridge C4, 3.5 μm, 300 Å stationary 
phase under ion pairing (0.05% TFA in H2O and MeCN) mobile phase conditions, utilizing a linear 
elution gradient (5-70%) with detection at 214 nm. 
 
3.2.3. Biophysical Characterization 
Determination of protein concentrations was done with ε280 nm (3 mL⋅g−1⋅cm−1) for p79. For 
derivatized polymers, the concentrations were determined on a total peptide basis (the same 
absorbance) so that the total concentration of p79 is unchanged. Other polymers and fluorescence 
concentrations were determined by weight. 
 
3.2.3.1. Far UV Circular Dichroism (CD)  
Far UV circular dichroism spectroscopy was performed using an Applied Photophysics 
Chirascan equipped with a 6-cell holder (Applied Photophysics, Leatherhead, UK).176 Peptides 
were at concentrations of ~0.1 mg/ml, in phosphate buffer (pH= 7.0), in a 1-mm quartz cell.  CD 
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was measured from 195 – 250 nm and using a 1 nm step size with a two second integration time 
at each step. Finally, corresponding buffers were subtracted for each sample.  
 
3.2.3.2. Dynamic Light Scattering (DLS)  
Dynamic light scattering was performed using a DynaPro Plate Reader (Wyatt Technology, 
Santa Barbara, CA).177 Incident light was detected in a backscattering configuration and analyzed 
with an autocorrelator. 20 µL of sample, in phosphate buffer (pH= 7.0), was placed in a clear-
bottomed 384 well plate and read at 20°C. Samples were measured 5 times with a 15 second 
acquisition time. Autocorrelation functions were fit using cumulant analysis and intensity averaged 
values are reported. Errors are reported as standard deviation of 3 replicates. 
 
3.2.3.3. Intrinsic Fluorescence Spectroscopy 
Intrinsic fluorescence was measured as described previously176 using custom fluorescence 
plate reader (Fluorescence Innovations, Minneapolis, MN). Briefly, a 285 nm laser was used to 
excite samples and fluorescence was collected at 180° after passing through a 310 nm longpass 
filter to block excitation light. A prism dispersed light onto a CCD to quantify the fluorescence as 
a function of wavelength. 10 µL of sample, in phosphate buffer (pH= 7.0), was placed in a 384 
well plate and covered with 2 µL of silicon oil to prevent sample evaporation. The fluorescence 
was measured from 10 to 90°C with a step-size of 1.25°C and an equilibration step of 2 min 
between each temperature. The total intensity from 300 to 400 nm was averaged for each 





NOD (Jax #001976), BDC2.5 T cell receptor (TCR) transgenic mice (Jax #004460) and 
NOD.CD45.2 congenic mice (Jax #014149) were purchased from The Jackson Laboratory. NOD. 
IL-10/GFP (“Tiger”) mice were kindly provided by Pere Santamaria178. BDC2.5.IL-10/GFP mice 
were produced by crossing NOD.IL-10/GFP mice with BDC2.5 mice. All mice were handled 
accordioning Columbia Center for Translational Immunology’s animal barrier facility. Both male 
and female mice between 6-12 weeks of age were used as donors for the splenocytes used in all 
experiments. All mice used in this study were handled according Columbia University Institutional 
Animal Care and Use Committee recommendations and approved protocols.  
 
3.2.5. T cell stimulation assay 
Splenocytes from NOD and NOD.BDC2.5 mice were subjected to ACK (Ammonium-
chloride-potassium) buffer to lyse red blood cells, filtered through a 70 µm cell strainer and 
resuspended into complete RPMI medium (containing 10% FBS, 50 IU/ml penicillin, 50 g/ml 
streptomycin, 2 mM L-glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate and 
0.05 mM 2-Mercaptoethanol). The splenocytes were counted and labeled with a violet cell 
proliferation dye eFluor450 (VCPD) (10 µM for 15 min, eBioscience). VCPD-labeled splenocytes 
were cultured at 2x105 cells/well with or without 100 nM of SAgAp79, cSAgAp79 or HA in U bottom 
96-well plates in triplicates. After 3 days of culture in a humidified CO2 incubator at 37°C, the 
supernatants were collected and kept at -20ºC for cytokine analysis. The splenocytes were 
harvested and stained with antibodies to CD4, CD25, CD44 and CD69 (Biolegend) and CD4+ T 
cell responses were analyzed by flow cytometry (FCM) on BD Fortessa. From collected 
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supernatants, cytokine concentrations (IL-2, IL-10 and IFN-γ) were measured by ELISA (MAX 
kits, Biolegend) according to manufacturer guidelines.  
 
3.2.6. Cellular uptake 
 Splenocytes were isolated from NOD or BDC2.5 mice as above, and cultured at 2x105 cells 
per well (U-bottom 96-well plates) in complete RPMI medium with or without fcSAgAp79 at 0.1-
1µM final concentration in humidified CO2 incubator at 37°C. Cells were harvested at 12 or 24h 
time points, washed twice in FACS buffer (PBS, 2% bovine serum, 0.05% sodium azide) to 
remove unbound fcSAgAp79 and stained with antibodies to CD45, B220, CD11c, CD11b, CD8a, 
F4/80, CD40 and CD86 (Biolegend). Samples were then analyzed on Fortessa for fcSAgAp79 
uptake by various cell types. Moreover, expression of costimulatory molecules CD86 and CD40 
was measured to assess activation of various APCs.  
 
3.2.7. APC subset-specific antigen presentation 
Splenocytes from NOD mice were prepared as above and cultured at 2x105 cells/well 
with/without SAgAP79 or cSAgAP79 at 1 nM concentration (limiting low dose to better identify the 
most efficient APCs). After 24h, the cells were harvested, washed twice, stained with antibodies 
against CD8, B220, CD11c, CD11b, CD45 and Gr1 and sorted into eight populations (BD Influx 
sorter). Finally, 103 sorted cells from each sorted population were co-cultured with 50,000 purified 
T cells/well (10% CD4+ CD25- T cells from BDC2.5 mice and 90% CD4+ CD25- and CD8+ T 
cells from NOD.CD45.2 mice) for 4 days. T cell purification was performed with MoJoSort 
magnetic cell separation kits (mouse CD4 T cell and CD3 T cell isolation kits, respectively, both 
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supplemented with biotinylated anti-CD25). The analysis of T cell response was performed by 
FCM as described above. 
 
3.2.8. Peptide and SAgA titration 
Splenocytes from NOD.BDC2.5.IL-10/GFP and NOD.CD45.2 mice were prepared as 
described above, labeled with VCPD (eBioscience) and mixed (10% and 90% respectively). The 
splenocytes were co-cultured (2x105 total cells/well) in the presence/absence of titrated SAgAP79 
or cSAgAP79 or their corresponding free peptide at 10-fold serial dilutions ranging from 10 pM to 
1µM concentrations. After 3 days of co-culture, the supernatants were removed for cytokine 
analysis and kept at -20°C. The splenocytes were collected, stained with antibodies to CD45.1 (to 
distinguish antigen-specific CD4+ T cells from bystander CD45.2+ T cells), to CD25 and CD44 
(activation) and to Lag-3 and PD-1 (immune checkpoint markers) and analyzed by FCM. The 
gating strategy shown on Figure S5). Secreted cytokines (IL-2, IFN-γ and IL-10) in stored 
supernatants were quantified by ELISA (as above). 
 
3.2.9. Statistical Analysis 
GraphPad Prism was used to perform statistical analysis including sigmoidal nonlinear 
regression, ordinary one-way or two-way analysis of variance (ANOVA), and unpaired t-test.  
ANOVA was followed by Tukey’s or Sidak’s post-hoc test, where appropriate. The threshold for 




3.3. Results and Discussion 
3.3.1. Structural design of click soluble antigen arrays 
Hydrolyzable multivalent soluble antigen arrays (SAgAp79) and the non-hydrolyzable 
(cSAgAp79) version are synthesized by conjugating approximately 10- 11 p79 peptides to a 16 kDa 
HA linear polymer. The valency was designed based on studies by the Dintzis group, which 
suggested a multivalent linear polymer with a valency of 10-20 antigens and a molecular weight 
(MW) less than 100 kDa could induce tolerogenic immune responses.162, 179-180 Studies done by 
Judkowski et al. identified multiple sequences from a peptide library that were able to stimulate T 
cells from transgenic BDC2.5 NOD mice, with the most stimulatory one known as the p79 
mimotope (AVRPLWVRME).170, 181 We have previously reported hydrolyzable SAgAPLP and non-
hydrolyzable cSAgAPLP constructed via aminooxy chemistry and CuACC linker chemistry, 
respectively, to conjugate PLP139-151 peptide to HA. Our studies pointed to superior efficacy of 
non-cleavable SAgAPLP that can sustain BCR engagement, thus prolonged interaction on the cell 
surface of B cells in EAE model.32 With our previous SAgA work in mind, our new SAgAs for 
T1D were designed by conjugating p79 (aoP79/hpP79) to HA via aminooxy chemistry or CuAAC 
chemistry. While the underlying pathogenesis and immune processes differ between MS and T1D, 
the novel delivery of autoantigen via SAgAs technology was expected to deliver similar benefits. 
Our ASIT was designed to target diabetogenic T cells implicated in disease initiation and 
progression in the NOD mouse model of T1D. 
 
3.3.2. Analytical characterization of click soluble antigen arrays 
Characterization was completed using various analytical techniques. 1H NMR was utilized 
to confirm the successful CuAAC conjugation of all the starting materials to furnish cSAgAp79 
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(Figure 20). The peak at 7.8 ppm for cSAgAp79, highlighted in yellow, is consistent with previously 
reported proton chemical shift for a triazole proton. This peak was not seen in any of the starting 
 materials since it can only form after the successful CuAAC reaction between the azide (HA-N3) 
and alkyne (hpP79). Resonance of both starting materials are seen in the final product highlighted 
 in green (hpP79), purple (HA- N3), and blue (PEG3).  
Figure 20: 1H NMR spectra of starting materials and the reaction product.  Resonances from the peptide starting 








1H/13C Heteronuclear Single Quantum Coherence (HSQC) NMR spectroscopy was used 
qualitatively to confirm the existence of resonances present in peptide sample hpP79 and HA-N3, 
which were carried over to the final dialyzed products cSAgAp79 and fcHAp79. These experiments 
affirm the complete absence of the terminal alkyne resonance from the terminal alkyne of the 
homopropargyl linker on the mimotope at (Figure 21A; δ(1H) ≈ 2.9 ppm, δ(13C) ≈ 70 ppm) in both 
the fluorescent and non-fluorescent cSAgAp79 products. These experiments in combination with 
the 1H NMR confirm the final product contains only the conjugated peptide of non-hydrolyzable 
Figure 21: HSQC NMR spectra of starting materials and the product fcSAgAp79 and cSAgAp79.  Resonances from the 
peptide starting materials are present in the final compounds for both fcSAgAp79 and cSAgAp79. The alkyne peak found 






cSAgAs. 1H NMR was not used to confirm successful conjugation of hydrolyzable SAgAp79 due 
lack of material, however, RP-HPLC was sufficient to show successful conjugation. 
Quantitative analysis of peptide conjugation efficiency was done using a RP-HPLC by 
measuring the decrease in peak area of the peptide throughout the course of the reaction (Figure 
S1: Supplementary Info). In CuAAC chemistry, Cu1+, which is a catalyst that allows the reaction 
to proceed, is generated in situ upon the addition of NaAsc, the reducing agent, to an inactive Cu2+ 
in solution. An aliquot of the reaction mixture was removed before the final NaAsc addition step, 
for HPLC analysis to establish a baseline response correlating to the molar excess of peptide used 
in the reaction. Thus, following the addition of NaAsc, any decrease in peak area of free alkyne-
containing peptide (hpP79) was attributed to conjugation. A small aliquot pre-NaAsc was taken 
from the reaction mixture as a control sample. hpP79 displayed <5% degradation (2.7%) at 37°C 
for 24 hours, demonstrating a minimal impact of peptide degradation on the accuracy of the 
analytical methodology. Bioconjugation optimization, which is required to achieve the desired 
peptide conjugation to HA-N3 (11 peptides), was performed by testing various conditions such as 
buffer type, temperature, reactant concentrations, and molar excess of free peptide. From these 
observations, the desired peptide valency in cSAgAp79 (11 p79) and fcSAgAp79 (7:1; p79:FTUA) 
were identified. Similar to CuAAC reaction, the aminooxy reaction was tracked by measuring the 
decrease in peptide. The increased retention time of the bioconjugates following peptide 
conjugation (Figure S1) correlates with increased product hydrophobicity. The hydrophilic 
polymer backbone comprises only ~32% by mass of the SAgA but has a significant effect on 
hydrophilicity. Unlike the CuAAC, milder conditions were used thus negligible degradation of 
peptide was seen via RP-HPLC. The reaction between the aminooxy peptide (aoP79) and HA was 
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a one-step reaction resulting in the final desired peptide valence of SAgAp79 (10 p79) and fSAgAp79 
(8:2; p79:FITC). See Table 1 for more information.  
To better understand the biophysical properties of the SAgAs, a few experiments were 
performed at physiologically relevant pH (7.4). Circular dichroism (CD) experiments were 
performed to evaluate the secondary structure of the bioconjugates (Figure 22A, 22B). CD 
revealed no significant secondary structure for the non-peptide components found in the SAgAs 
(data not shown), which include HA, HA-N3, triazole, FTA, and FTUA. The CD spectra of hpP79 
and aoP79 both exhibited the presence of random coil, which is consistent with small peptide 
secondary structure in literature. However, the modified peptides secondary structures were 
different, possibly because of the differences in the hydrophobicity of the modification. Both 
cSAgAs (Figure 22A) also exhibited a random coil structure but differ slightly from their parent 
peptide (hpP79). This may be due to the conjugation of peptides to HA resulting in loss of 
rotational freedom and decreased entropy of peptides in solutions. Both SAgAp79 and aoP79 
(Figure 22B) showed similar secondary structure to the cSAgAs. The loss of the hydrophobic 
homopropargyl linker upon conjugation to HA-N3 makes the cSAgAs more hydrophilic, which 
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may explain the similar secondary structure to both aoP79 and SAgAp79. fSAgAp79 did not follow 
this trend. 
Experiments studying the intrinsic fluorescence (Figure S2) of the SAgA revealed no 
transition state change. fcSAgAp79 showed a significant difference in intensity due to the conjugated 
fluorophore. Finally, DLS data (Table 3) revealed reasonable increases in size of SAgAs compared 
to starting materials. Interestingly, HA (16 kDa) when compared to HA-N3 (24.5 kDa) was shown 
to be larger (nm). All SAgAs showed a significant amount of aggregation in physiological pH (7.4) 
and high heterogeneity. Both the hydrolyzable fSAgAs and non-hydrolyzable fcSAgA showed a 
significant increase in average size when compared to their non-fluorescent counterparts, which 














Radius (nm) %Polydispersity 
hpP79 
                      
1.335 0 0 0.82 ± 0.02 14.3 
aoP79 
                        
      
1.3287 0 0 0.82 ± 0.02 4.1 
P79k 
                        
 
1.3287 0 0 NA NA 
HA-N3 
 




16.0 0 0 7.3 ± 0.03 57.1 
Table 3. Peptide molar conjugation of hydrolyzable and click conjugates, as determined by RP- HPLCa .Dynamic 





      
39.7 10.7 0 17.6 ± 0.01 Multimodal 
fcSAgAp79 
 
      
33.8 7 1 81.3 ± 0.03 Multimodal 
SAgAp79 
 
      
27.99 9.6 0 70.9 57.0 
fSAgAp79 
      
      
30.1 8.2 1.8 178.4 ± 5.5 53.8 
SAgAp79k  
 
      
      
30.1 10 0 NA NA 
a Results are an average of triplicate injections from a single batch preparation. In the molecule 
schematics, dotted lines represent hydrolyzable oxime linker chemistry while solid lines represent 
non-hydrolyzable ‘click’ linker chemistry. 
b Calculated from RP-HPLC data. MW, molecular weight. 
c HA, hyaluronic acid; p79 
d DLS data were collected in triplicate 
 represents florecent dye. 
 
3.3.3. Specificity of T cell responses to SAgA-derived epitopes 
To validate the ability of the p79 epitope grafted on SAgAs to elicit an antigen-specific T 
cell response, we cultured splenocytes from NOD and BDC2.5 mice with one of the p79-SAgAs 
or with the corresponding ‘naked’ HA molecule. The specificity was demonstrated by both the 
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lack of response of BDC2.5 T cells to HA and the lack of response of NOD T cells to cSAgAP79 
in terms of activation markers (Figure 23A,B) and cytokine production (Figure 23C-E). 
 
Figure 23. Antigen-specific CD4+ T cells responses to cSAgAp79 in vitro. Representative plots (A) and summary of 
triplicates samples (B) showing upregulation of CD25, CD44 and CD69 in CD4+ T cells from BDC2.5 mice as 
compared NOD mice after 12h of culture. (C-E) Cytokine secretion at 12h and 24h of culture: IL-2 (C), IL-10 (D) 
and IFN-γ (E). The values are given as mean ± SD (n=3 technical replicates).  
  
3.3.4. Uptake of SAgAs by different spleen cell populations 
We then used FITC-conjugated SAgAs to compare the ability of different cell populations 
within the spleen to capture SAgAs (Figure S3). After up to 24h incubation in vitro, splenocytes 





Initially, all antigen-presenting cell (APC) populations (B cells, macrophages/monocytes, 
pDCs and cDCs) but not T cells from NOD splenocytes were found to take up SAgAs (Figures 
24A,B; S5A,B). However, uptake by BDC2.5 splenocytes was increased as early as 12h for 
macrophages/monocytes, and later (by 24h) for other cells including T cells. Given that T cell 
activation was evident as early as 12h with BDC2.5 splenocytes (Figure 23), we hypothesized that 
antigen-specific T cell activation (possibly through cytokine release) stimulated other immune 
cells, leading to increase endocytosis. Indeed, the increased uptake of SAgA by BDC2.5 
splenocytes was associated with increased expression of the maturation molecules CD40 and 
CD86 at 12-24h (Figures 24C,D; S5C) and increased cell size at 24h (Figures S5A vs S5B). 
Importantly, SAgAs were not responsible for APC maturation because they had no effect on NOD 
splenocytes in terms of CD40/CD86 expression (Figures 24C,D; S5C) and cell size (Figures S5A 
 
Figure 24.  Uptake efficiency of fcSAgAp79 (1 M) by different APCs at 12h (A) and 24h (B) time points and 
upregulation of costimulatory molecules CD40 (C) and CD86 (D) at 24h. Control cells from NOD mice are not 
shown (comparable to BDC2.5 control). The values are given as mean ± SD (n=3 technical replicates) and the data 
are representative of two experiments performed with fcSAgAp79, and experiments performed with FITC-
conjugated SAgAp79. MMN: monocytes, macrophages, neutrophils. 
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vs S5B). Thus, these SAgAs do not have inherent immunogenic adjuvant properties, a prerequisite 
for tolerance induction. 
 
3.3.5. Presentation of SAgA-derived epitopes by spleen APCs 
Given that most cell types were able to take up SAgAs provided at high dose (100 nM – 1 
M), we then asked what APC subsets are most effective at processing and presenting SAgA-
derived epitopes, using a limiting dose (1 nM) that would be more in line with in vivo conditions. 
Following culture of NOD splenocytes with SAgAp79 or cSAgAp79 (no noticeable T cell response), 
the cells were sorted into 8 populations, as shown on Figure S5, and each purified population was 
cocultured with purified CD4+ CD25- T cells from BDC2.5 mice. Antigen-specific T cell 
stimulation was only detected with cDC subsets (Figure 25). Moreover, cSAgAp79 was more 
 
Figure 25: Conventional DCs (cDC1 and cDC2) most efficiently present epitopes from SAgA to CD4+ T cells as 
compared to other APCs. Representative dot plots depicting proliferation and CD25 upregulation by antigen-
specific BDC2.5 CD4+ T cells (A), and summary bar graphs of BDC2.5 CD4+ proliferation (B) and upregulation 
of CD25 (C) and CD44 (D). The values are given as mean ± SEM (n=3 technical replicates).  
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stimulatory than SAgAp79 (Figure 25). This was somewhat surprising as epitopes were not 
expected to be released as easily with the covalent link relative to the hydrolyzable link. 
 
3.3.6. Stimulatory activity of SAgA variants and their corresponding peptides 
In the light of apparent stimulatory superiority of cSAgAp79 over SAgAp79, we conducted 
a titration of these two SAgAs along with their respective peptides, which had different 
modifications prior to grafting to HA. CD4+ T cells (10%; from BDC2.5 mice with IL-10/GFP 
reporter) were diluted with non-specific T cells (90%; from NOD.CD45.2 mice) serving as internal 
negative controls for T cells (gating strategy shown on Figure S6). 
 As negative control for antigen, we use SAgAp79k containing an immunologically killed 
version of p79 with two amino acids permuted (p79k). Soluble peptides (aoP79 used to make 
SAgAp79 and hpP79 used to make cSAgAp79) were compared with the non-modified p79 and mixed 
together with the HA molecule used to make SAgA (HA with p79 and aoP79 and HA-N3 with 
hpP79). Because each SAgA molecule bears 10-11 peptides, we represented all concentrations as 
peptide-equivalent (e.g. 1 nM SAgA = 10-11 nM peptide), and for free peptide / HA mixtures, we 
use 10-fold less HA than peptide to achieve the same relative amount as with SAgAs. The controls 
SAgAp79k and p79k+HA did not induce any T cell response (Figures 26 and S7), again highlighting 
the highly specific nature of the response. p79, aoP79 and SAgAp79 induced a similar T cell 
response (based on proliferation and surface markers) that was most evident at 1-10 nM, while 
hpP79 and cSAgAp79 were the most stimulatory, with T cell responses measurable at 10-100 pM 




We generally found that the free peptide was more stimulatory than its SAgA form at 
equivalent concentrations. However, at higher doses, SAgAs induced a greater PD-1 upregulation 
than their respective free peptide (Figure 26E). No significant stimulation was observed in 
bystander CD45.1- T cells (polyclonal T cells from NOD.CD45.2 mice; Figure S7). The cytokine 
response required higher doses of peptide or SAgA (at least 10 nM for IL-10 and IFN-, and 100 
nM for IL-2), and in this case, SAgA were at least as stimulatory if not better than their 
corresponding free peptide (Figure 26F-I). Overall, the results suggest that cSAgAp79 may be more 
 
Figure 26: Dose-response curves of BDC2.5 CD4+ T cell responses (gated on CD45.1+ cells) induced by SAgAp79 
and cSAgAp79 compared to their respective peptide aoP79 and hpP79 after 3 days in vitro culture: proliferation 
based on VCPD dilution (A), upregulation of CD25 (B), CD44 (C), Lag-3 (D), PD-1 (E), and IL-10/GFP (F), 
secretion of IL-10 (G), IL-2 (H) and IFN-γ (I). The values are given as mean ± SD (2-3 technical replicates per 
experiment). Data are representative of 2-3 experiments for each molecule with at least two batches tested for most 




potent than SAgAp79 not because of the difference in release mode but rather because of the N-
terminal modification of p79. 
 
3.4. Conclusion 
Both hydrolyzable and non-hydrolyzable SAgAs were characterized and evaluated in vitro 
as therapeutic agents to target diabetogenic BDC2.5 T cells as representative autoreactive T cells 
in the NOD mouse model of T1D. Biophysical properties of both versions of non-fluorescent 
SAgA varied slightly. CD spectra for both hydrolyzable SAgAp79 and non-hydrolyzable cSAgAp79 
were shown to be similar to the aoP79. Neither appeared to have any transition state when tested 
via a temperature fluorescent gradient. Both versions appeared to be heterogeneous and prone to 
aggregation. 
Our in vitro immunoassays demonstrated that SAgA-derived epitopes were efficiently 
presented to specific T cells. T cell responses were generally greater with soluble peptide because 
of the high local concentration at which some free peptide may bind directly to MHC-II via 
spontaneous peptide exchange, whereas SAgAs require endocytosis, degradation and processing 
before loading onto MHC. We initially postulated that the distinct peptide grafting chemistries 
between SAgAp79 and cSAgAp79 would influence their immunological properties. Indeed, the 
ability of SAgAs to bring in bundled peptides inside the cells and release them should be affected 
by the balance of extracellular versus endosomal degradation. Excessive extracellular and/or 
insufficient endosomal degradation could limit the antigen load. Hydrolyzable SAgAs are 
expected to release their peptide cargo under the endosome’s low pH, while the covalent linker is 
not expected to be broken down by any known enzymes. Both SAgAs and cSAgAs are susceptible 
to degradation at the level of the HA backbone by extracellular and endolysosomal hyaluronidases. 
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Thus, differences in stimulatory activity may be determined by how much peptide is effectively 
taken up and loaded on MHC. However, when comparing the stimulatory activity of two modified 
peptides used to produce these two forms of SAgAs, namely the aminooxy and alkyne versions, 
we observed that the alkyne form of the peptide was significantly more stimulatory. While the N-
terminal aminooxy residue did not seem to have any effect on T cell stimulation relative to the 
unmodified p79 peptide, the N-terminal alkyne could possibly interact with the outside of the 
MHC-II molecule, forcing the peptide to bulge and facilitating interactions with the BDC2.5 TCR. 
As both hpP79 and cSAgAp79 are more stimulatory, it would be surprising that both the alkyne 
motif (C≡C) and the cyclic motif resulting from reaction with azide would have the same effect 
on tweaking the overall epitope conformation. 
In vitro, both SAgAs could promote the upregulation of immune checkpoint receptors like 
PD-1 and Lag-3, which may help predispose the targeted T cells to tolerance induction by their 
ligands. Nevertheless, further studies will be required to address how the antigen-specific T cells 
respond to those SAgAs in the in vivo environment in the context of T1D development. While in 
vitro stimulation was expected to favor soluble peptides for the reasons provided above, it is 
expected that SAgAs will be more stimulatory in vivo due to reduced diffusion, greater peptide 







Figure S3. Gating strategy for different spleen populations assessed for fcSAgA uptake.  
Figure S1 A: Reverse-phase analytical high-performance liquid chromatography (RP-HPLC) of SAgAp79 formation 
(broad black peak at 9.20 min) compared to initial hpP79 (blue peak at 9.3min) on an xBridge C4 5um (4.6X250mm) 
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Figure S2: Intrinsic florescence of SAgA and components found within each SAgA 
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Figure S4A,B: Representative dot plots of in vitro FITC-cSAgAp79 uptake various immune populations within the 





Figure S4C. Representative dot plots illustrating the activation of various NOD and BDC2.5 spleen cell populations 




Figure S5. Gating strategy for the sorting of NOD splenocytes after incubation with p79-containing SAgAs for 24h 




Figure S6. (A) Gating strategy to evaluate CD4+T cell responses to SAgAs and their respective peptides. (B-G) 
Dose-response curves of BDC2.5 CD4+ T cell responses (gated on CD45.1+ cells) induced by soluble peptides 
mixed with soluble HA, including unmodified p79, aoP79 (with linker for hydrolysable SAgA), hpP79 (with linker 
for covalent SAgA) and immunologically inactive P79k (with two amino acid permutations), at various 
concentrations. Splenocytes from BDC2.5 IL-10/GFP reporter mice were cultured with each peptide for 3 days. 





Figure S7. Representative dot plots for some of the markers measured at selected concentrations illustrating 
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CHAPTER 4: SYNTHESIS AND BIOPHYSICAL CHARACTERIZATION OF MULTIVALENT PROTEIN 
BASED SOLUBLE ANTIGEN ARRAYS FOR JUVENILE DIABETES 
4.1. Introduction 
Autoimmune diseases, such as multiple sclerosis (MS),182-183 type 1 diabetes (T1D),184-188 
neuromyelitis optica (NMO),189-190 and systemic lupus erythematosus (SLE),191-192 implicate loss 
of tolerance to self-antigen in autoreactive B cells, which leads to host tissue damage, disability, 
and death. In individuals afflicted by T1D, the insulin producing beta cells in the pancreas are 
targeted by an abnormal immune response, resulting in cell death.184 It has been reported that 
autoantibodies are a strong predictor of the development of T1D. No studies have shown such 
antibodies to be pathogenic; studies have suggested B cells may contribute to the development of 
disease via their antigen presenting function and/or cytokine production.184-188 Rituximab works 
by depleting B cells and has been used to treat certain autoimmune disease such as T1D. However, 
the monoclonal antibody causes global B cell depletion, leading to adverse side effects, and has 
limited efficacy.193-195 Antigen-specific immune therapy (ASIT) has emerged as a potential means 
to selectively induce immune tolerance,28, 38 via an intervention similar to allergy shot therapies, 
which use soluble antigens to restore tolerance towards specific antigens.152 In particular, strategies 
to engage and selectively tolerize or delete autoreactive B cells offer a promising approach to 
ASIT. 
Dintzis and co-workers studied the delivery of antigens bound to polymers, and they 
reported two different antigen-specific responses dictated by the following properties: polymer 
molecular weight, solubility, and antigen valency and spacing. An immunogenic response was 
seen when polymer delivering haptens were large (>100 kDa), rigid, and poorly soluble. A 
tolerogenic effect occurred when polymer delivering haptens were smaller (<100 kDa), flexible, 
soluble, and often with relatively lower hapten density.162, 196-198 Interestingly, the molecular 
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properties that encourage immune tolerance are also favorable for accessing B cell compartments 
in secondary lymphoid organs (<100 kDa)199-200 and promote selectivity to antigen-specific B cells 
over other professional antigen presenting cells (pAPCs). We rationalized an antigen delivery 
system exhibiting molecular properties capable of inducing tolerance by engaging antigen-specific 
B cells may be a viable therapeutic for T1D. 
Our group has previously reported a novel antigen delivery system known as Soluble 
Antigen Arrays (SAgAs), which were originally designed with ‘Dintzis rules’ in mind as ASIT for 
MS. SAgAs are constructed via a hydrophilic linear polymer hyaluronic acid (HA) grafted with 
multiple repeating autoantigen (proteolipid protein peptide, PLP139-151).
64, 154, 163-169 SAgAPLP 
induced tolerance and suppressed disease progression in many studies conducted in experimental 
autoimmune encephalomyelitis (EAE), a model used to mimic MS in humans. Our studies 
ultimately pointed toward SAgAs engagement of B cell receptor (BCR) in an antigen-specific 
manner. cSAgAPLP constructed via a non-hydrolyzable linker chemistry rather than a hydrolyzable 
linker (SAgAPLP) showed greater binding in vitro to B cells and greater disease suppression in 
vivo.64, 154 
We hypothesized that SAgAs composed of multiple repeating human insulin conjugated 
via non-degradable linker chemistry to HA may silence or delete B cells obtained from non-obese 
diabetic (NOD) mice transgenic for anti-insulin immunoglobulin heavy chain (VH125.NOD). 
Human insulin was conjugated onto HA via Copper-catalyzed Azide-Alkyne Cycloaddition 
(CuAAC) linker chemistry. SAgAIns with different valency were synthesized and their biophysical 
properties were studied. Specificity of SAgAIns was determined in B cells from both 125Tg (NOD) 
and VH125.NOD mice in order to confirm their ability to ligate to BCR on the surface of IBCs. 
To further validate specificity, B cells (CD43-) purified from spleens of VH125.NOD mice and 
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MD4 B cells (hen egg lysozyme (HEL) reactive) were mixed in at approximately the same 
frequency as IBCs. SAgAIns was observed to block binding of insulin to IBCs but not HEL binding 
to MD4 B cells. Lastly, to determine if SAgAIns can induce antigen-specific tolerance, and if there 
is valency dependence, ex vivo B cells from 125Tg mice were cultured in vitro with or without 
SAgAIns, or HA alone. These cells where subsequently assayed for surface levels of BCR as well 
as other markers to determine BCR stimulation or anergy.   
 
4.2. Materials and Methods 
Cell PrimeTM r-insulin recombinant human insulin was purchased from EMD Millipore 
Corporation (Chicago, IL). N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC), 2-(N-morpholino)ethane-sulfonic acid sodium salt (MES), tris(3-
hydroxypropyltriazolylmethyl)amine, sodium ascorbate (NaAsc), and Propargyl-N-
hydroxysuccinimidyl ester were purchased from Sigma-Aldrich (St. Louis, MO) and used as 
received without further purification. Hyaluronic acid (HA) sodium salt (MW 16 kDa) was 
purchased from Lifecore Biomedical (Chaska, MN). 11-azido-3,6,9-trioxaundecan-1-amine (NH2-
PEG3-N3), N-hydroxysuccinimide, Copper (II) sulfate pentahydrate (CuSO4 • 5H2O) was 
purchased from Acros Organics (Geel, Belgium). Alkyne-functionalized peptide bearing an N-
terminal 4-pentynoic acid (homopropargyl, hp) modification, hpPLP139-151 (hp-
HSLGKWLGHPDKF-OH) was originally synthesized in our laboratory via solid phase peptide 
synthesis. Larger quantities of hp PLP139-151 peptide was obtained from Biomatik USA, LLC 
(Wilmington, DE). VH125.NOD and MD4 mice were purchased from The Jackson Laboratory 
and 125Tg mice were a kind gift from the laboratory of Dr. Rachel Friedman (National Jewish 
Health, Department of Biomedical Research). CD43 negative selections were purchased from 
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Miltenyi Biotec and Millipore Sigma respectively. B76 and HM79 were produced in the Cambier 
laboratory and were directly conjugated to fluorochromes (Thermo Fisher Scientific). 5 uM Indo-
1 acetoxymethyl calcium indicator were purchased from Molecular Probes. All other chemicals 
and reagents were analytical grade and used as received. 
 
4.2.1. Synthesis and Labeling of Soluble Antigen Arrays 
Soluble antigen arrays (SAgAs)- and fluorescein isothiocyanate (FITC)-labeled SAgAs 
(fSAgAs) were synthesized and characterized as previously reported. Peptide conjugation was 
determined through gradient reverse-phase analytical high-performance liquid chromatography 
(RP-HPLC). Relative FITC fluorescence of labeled samples was determined 
spectrofluorometrically. 
 
4.2.1.1. Synthesis of Alkyne-Functionalized Human Insulin (FTUA) 
 
Figure 27: Reaction scheme for the synthesis of FTUA. 
Synthesis of 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-(3-(prop-2-yn-1-yl)thioureido) 
benzoic acid (fluorescein thiourea alkyne; FTU-Alk) was adapted from Meng et al.140 To a mixture 
of  FTUA (200mg, 511.4 µmol) and 1-amino-11-azido-3,6,9-trioxa-undecane (131mg, 119.09 μL, 
0.616 mmol) in DMSO (1 mL) was added triethylamine (75 μL, 0.514 mmol), and the mixture 
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was stirred for 2 h at room temperature in the dark. The reaction mixture was then frozen at -20°C 
and lyophilized to afford a red oil. The crude product was dissolved in DMSO and purified by 
preparative RP-HPLC (Waters XBridge C18, 5 µm, 10x250 mm, linear gradient from 5-95% 
MeCN (+ 0.05% TFA) in H2O (+ 0.05% TFA) over 20 minutes, detection at 280 nm) to give the 
final product (176.5 mg, 7%) as a red-oil; 1H NMR (500 MHz, DMSO-d6) δ 7.82-7.78 (m, 1H), 
7.83-7.77 (m, 2H), 7.05-7.00 (m, 1H), 6.42-6.26 (m, 6H), 7.11 (d, J =  2.4 Hz, 1H), 7.08 (d,  J =  
2.4 Hz, 1H), 7.03 (s, 1H), 7.00 (s, 1H), 6.97 (d, J = 2.4 Hz, 1H), 3.65 (q, J = 7.14, 7.06, 7.06 Hz, 
2H), 3.77 (d, J = 2.5 Hz , 2H), 2.70-2.63 (m, 8H), 2.66 (t, J = 2.5, 2.5 Hz, 1H)1.08 (t, J = 6.95, 
6.95 Hz, 12H); HRMS expected [M+H]+: 445.0853, found: 445.0858. 
 
4.2.1.2. Synthesis of Alkyne-Functionalized Human Insulin (Ins-Alk) 
 
Figure 28: Reaction scheme for the synthesis of Ins-Alk. 
Synthesis of Ins-Alk was adapted from Patent No.: US 8,906,850 B2. 120.00 mg of 
powdered human insulin is dissolved in 3000 µL of anhydrous DMSO at room temperature 
followed by the addition of 120 µL of triethylamine (TEA). The solution is stirred for 30 minutes 
at room temperature. Next, 1.2 equivalents (relative to human insulin) of propargyl-N-
hydroxysuccinimidyl ester is slowly added to the insulin-TEA solution as a 1.0 M solution of the 
propargyl-N-hydroxysuccinimidyl ester in THF. The reaction is mixed for 1 h and then quenched 
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via the addition of 9.7 µL of a stock solution containing 250 µL of ethanolamine in 5,000 µl of 
DMSO followed by mixing for five minutes.  (37.8 mg, 30.51%); MS (TOF ESI+) deconvoluted 
expected [M]+: 5918.66, found: 5918.66. 
 
4.2.1.3. Synthesis of Azide Functionalized hyaluronic Acid (HA-N3) 
 
Figure 29: Reaction scheme for the synthesis of HA-N3. 
Synthesis of HA-N3 was adapted from Hu et al and Di Meo et al. Sodium hyaluronate (93.9 
μmol, 16 kDa average MW) was added to a 250 mL round bottom flask with stir bar, followed by 
100 mL of 50 mM MES buffer (pH = 4.0). The mixture was stirred until in solution (~15 minutes) 
before EDC (23.1 mmol) was added neat, then N-hydroxysuccinimide (18.8 mmol) added neat. 
The mixture was stirred for 5 minutes before H2N-PEG3-N3 (4.51 mmol) in 20 mL MES buffer 
was added. The solution was then stirred for 24 hours at room temperature before being dialyzed 
in 6-8 kDa cutoff dialysis tubing against 4.5 L of 1.0 M NaCl solution for 24 hours, then 4.5 L of 
deionized water (4 x 12 hours). The volume in the bag was then transferred to vials, frozen, and 
lyophilized to yield a white powder (1.61 g, 95.0%). 
95 
 
4.2.1.4. Synthesis of Florescent Hyaluronic Acid (fHA-N3) 
 
Figure 30: Reaction scheme for the synthesis of fHA-N3 
 HA-N3 (2.0 μmol) was added as a 30 μM solution in phosphate buffer (pH= 7.0) to a 250 
mL round bottom flask with stir bar. Then hpP79 (40 μmol) was then added as a 3.52 mM solution 
in phosphate buffer (pH= 7.0), followed by FTUA (4 μmol), and then by a premixed solution of 
THPTA (70 μmol) and CuSO4 • 5H2O (14.5 μmol) in phosphate buffer (pH= 7.0). The solution 
was allowed to stir for 1-2 minutes before a 100 μL aliquot was removed for HPLC analysis. 
NaAsc (295 μmol) was then added to the reaction mixture as a 100 mM solution phosphate buffer 
(pH= 7.0). The reaction was allowed to 24 hours at room temperature. Additional 100 μL aliquots 
were removed throughout the course of the reaction to determine the extent of conjugation. Then 
the reaction solution was transferred to 6-8 kDa dialysis tubing and dialyzed against 4.5 L of 1.0 
M NaCl (3 x 8 hours), then 4.5 L of deionized H2O (6 x 8 hours). The volume in the bag was then 
transferred to vials, frozen, and lyophilized. 
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4.2.1.5. Synthesis of SAgA Insulin (SAgAIns) 
 
Figure 31: Reaction scheme for the syntheses of lvSAgAIns , mvSAgAIns and hvSAgAIns. 
 Three different reactions with 5 equivalents of Ins-Alk relative to HA-N3 (to make 
lvSAgAIns and mvSAgAIns) and 10 equivalents of Ins-Alk relative to HA-N3 (hvSAgAIns) were set 
up with the following conditions. HA-N3 (0.81 μmol) was added as a 15 μM solution in phosphate 
buffer (50 mM, pH= 7.0) to a 100 mL round bottom flask with stir bar. Followed by the addition 
of insulin-alkyne, a 4.0 mM or 8.1 mM solution in DMF (5 and 10 equivalents relative to HA-N3 
respectively) was also added. Then a premixed solution of THPTA (60 μmol) and CuSO4 • 5H2O 
(12 μmol) in phosphate buffer (50 mM, pH= 7.0) was added to the alkyne/azide mixture. Then a 
100 μL aliquot was removed for HPLC analysis. NaAsc (242 μmol) was then added to the reaction 
mixture as a 100 mM solution in phosphate buffer (pH= 7.0). One reaction with 5 equivalence of 
Ins-Alk relative to HA-N3 was stirred at room temperature for 24h until some alkyne component 
was consumed to furnish lvSAgAIns.  While two other reactions were stirred at elevated temperature 
(40°C) for 24 h until all alkyne component was consumed to produce both mvSAgAIns and 
hvSAgAIns. Additional 100 μL aliquots were removed throughout the course of the reaction to 
determine the extent of conjugation. Upon completion of the reaction, the solution was quenched 
by adding 0.5 mL of 50 mM EDTA, then transferred to 6-8 kDa dialysis tubing and dialyzed 
97 
 
against 4.5 L of 1.0 M NaCl (3 x 8 hours), then 4.5 L of deionized H2O (6 x 8 hours). The volume 
in the bag was then transferred to vials, frozen, and lyophilized. 
 
4.2.1.6. Synthesis of PLP Hyaluronic Acid (HA-PLP) 
 
Figure32: Reaction scheme for the synthesis of HA-PLP. 
 HA-N3 (0.37 μmol) was added as a 56 μM solution in phosphate Buffer (50 mM, pH= 7.0) 
to a 150 mL round bottom flask with stir bar. Followed by the addition of hpPLP, a 1.7 mM 
solution in DMF (5.0 equivalents relative to HA-N3) was also added to the solution. Then a 
premixed solution of THPTA (8.5 μmol) and CuSO4 • 5H2O (1.6 μmol) phosphate buffer (50 mM, 
pH= 7.0) was added to the solution. Then a 100 μL aliquot was removed for HPLC analysis. NaAsc 
(33 μmol) was then added to the reaction mixture as a 100 mM solution in phosphate buffer (50 
mM, pH= 7.0). The reaction was stirred at room temperature for 24h until the alkyne component 
was partially consumed (~3PLP per HA). Additional 100 μL aliquots were removed throughout 
the course of the reaction to determine the extent of conjugation. Upon completion of the reaction, 
the solution was quenched by adding 0.5 mL of 50 mM EDTA, then transferred to 6-8 kDa dialysis 
tubing and dialyzed against 4.5 L of 1.0 M NaCl (3 x 8 hours), then 4.5 L of deionized H2O (6 x 8 
hours). The volume in the bag was then transferred to vials, frozen, and lyophilized. 
98 
 
4.2.1.7. Synthesis of Florescent Ins hyaluronic Acid (fHA-Ins) 
 
Figure 33: Reaction scheme for the synthesis of fSAgAIns 
 fHA-N3 (0.81 μmol) was added as a 15 μM solution in phosphate buffer (50 mM, pH= 7.0) 
to a 100 mL round bottom flask with stir bar. Followed by the addition of insulin-alkyne, a 4.0 
mM in DMF (5 equivalents relative to fHA-N3) was also added. Then a premixed solution of 
THPTA (60 μmol) and CuSO4 • 5H2O (12 μmol) in phosphate buffer (50 mM, pH= 7.0) was added 
to the alkyne/azide mixture. Then a 100 μL aliquot was removed for HPLC analysis. NaAsc (242 
μmol) was then added to the reaction mixture as a 100 mM solution in phosphate buffer (pH= 7.0). 
The reactions were stirred at room temperature for 24h until the alkyne component was partially 
consumed (~2 Ins per HA). Additional 100 μL aliquots were removed throughout the course of the 
reaction to determine the extent of conjugation. Upon completion of the reaction, the solution was 
quenched by adding 0.5 mL of 50 mM EDTA, then transferred to 6-8 kDa dialysis tubing and 
dialyzed against 4.5 L of 1.0 M NaCl (3 x 8 hours), then 4.5 L of deionized H2O (6 x 8 hours). The 
volume in the bag was then transferred to vials, frozen, and lyophilized. 
 
4.2.2. Analytical Characterization of Click Soluble Antigen Arrays 
NMR spectra were collected on a Bruker Avance AVIII 500 MHz spectrometer equipped 
with a dual carbon/proton cryoprobe (unless otherwise noted), and all samples were dissolved in 
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650 μL of D2O for analysis.  MestReNova 11.0 was used for NMR data analysis. The amide methyl 
resonance (δ ~ 1.90-2.05 ppm) of all 1H NMR spectra was normalized to an integration of 3.0, and 
the sum of all other signals in the range of δ ~ 1.0-4.0 ppm was used to ratiometrically determine 
the number of azide functionalization sites during HA-N3 synthesis. 
RP-HPLC and SEC analysis were conducted using a Waters Alliance HPLC system 
equipped with either a diode array detector or dual wavelength UV/Vis detector. For the 










)             Equation 1 
where Ncon = number of conjugated peptides per backbone, npep = moles of peptide used in reaction, 
nHA = moles of HA-N3 used in reaction, Vpre = total reaction volume before NaAsc is added, Vsam 
= volume of “pre-NaAsc” sample removed from reaction mixture, PAt = measured peak area of 
peptide at time t, PAstart = measured peak area of free peptide before NaAsc is added to the reaction. 
General chromatographic conditions employed a Waters XBridge C4, 3.5 μm, 300 Å stationary 
phase under ion pairing (0.05% TFA in H2O and MeCN) mobile phase conditions, utilizing a linear 
elution gradient (5-70%) with detection at 214 nm. 
 
4.2.3. Biophysical Characterization 
Determination of protein concentrations was done with ε280 nm (3 mL⋅g−1⋅cm−1) for human 
insulin. For derivatized polymers, the concentrations were determined on a total protein basis (the 
same absorbance) so that the total concentration of insulin is unchanged. Other polymers and 




4.2.3.1. Far UV Circular Dichroism (CD)  
Far UV circular dichroism spectroscopy was performed using an Applied Photophysics 
Chirascan equipped with a 6-cell holder (Applied Photophysics, Leatherhead, UK).176 Proteins 
were at concentrations of ~0.1 mg/ml, in phosphate buffer (pH= 7.0) or acidic water (pH= 3.0), in 
a 1-mm quartz cell.  CD was measured from 195 – 250 nm and using a 1 nm step size with a two 
second integration time at each step. Finally, corresponding buffers were subtracted for each 
sample.  
 
4.2.3.2. Dynamic Light Scattering (DLS)  
Dynamic light scattering was performed using a DynaPro Plate Reader (Wyatt Technology, 
Santa Barbara, CA).177 Incident light was detected in a backscattering configuration and analyzed 
with an autocorrelator. 20 µL of sample, in phosphate buffer (pH= 7.0), was placed in a clear-
bottomed 384 well plate and read at 20°C. Samples were measured 5 times with a 15 second 
acquisition time. Autocorrelation functions were fit using cumulant analysis and intensity averaged 
values are reported. Errors are reported as standard deviation of 3 replicates. 
 
4.2.3.3. Intrinsic Fluorescence Spectroscopy176 
Intrinsic fluorescence was measured as described previously using custom fluorescence 
plate reader (Fluorescence Innovations, Minneapolis, MN).176 Briefly, a 285 nm laser was used to 
excite samples and fluorescence was collected at 180° after passing through a 310 nm longpass 
filter to block excitation light. A prism dispersed light onto a CCD to quantify the fluorescence as 
a function of wavelength. 10 µL of sample, in phosphate buffer (pH= 7.0), was placed in a 384 
well plate and covered with 2 µL of silicon oil to prevent sample evaporation. The fluorescence 
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was measured from 10 to 90°C with a step-size of 1.25°C and an equilibration step of 2 min 
between each temperature. The total intensity from 300 to 400 nm was averaged for each 
temperature. Error bars represent the standard deviation of 4 replicates. 
 
4.2.4. Mice 
Female mice, aged 6-8 weeks, were used in all experiments. VH125.NOD mice express, 
by virtue of knock-in, the variable heavy-chain region from the insulin specific 125 hybridoma, on 
the NOD background. Together with endogenous light chains, these mice bear ~3 % insulin 
reactive B cells in the periphery. 125Tg mice express both the heavy- and light-chain from the 125 
hybridoma, rendering 100 % of their peripheral B cells reactive to insulin. MD4 mice express both 
a heavy- and light-chain specific for hen-egg lysozyme (HEL); the sole antigen specificity of all 
B cells in this mouse. Mice were housed and bred at the University of Colorado Denver Anschutz 
Medical Campus Vivarium or in the Biological Resource Center at National Jewish Health. All 
experiments involving mice were performed in accordance with the regulations and with approval 
of the University of Colorado Denver Institutional Animal Care and Use Committee and National 
Jewish Health. 
 
4.2.5. Tissue harvest 
Spleens were harvested in IMDM supplemented with 5 % FCS, 1 mM sodium pyruvate, 
50 ug/mL gentamicin, 100 U/mL penn/strep, 2 mM L-glutamine, and 5E-5 M beta-
mercaptoethanol; single cell suspensions were prepared by mechanical disruption. RBC's were 
lysed with 1mL ACK (150 mM NH4Cl, 10 mM KHCO3, 100 mM Na2EDTA) for 1 min at room 
temperature (RT). Cells were subsequently washed and resuspended in either complete medium 
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containing 0.1 % NaN3 or complete medium alone for staining or calcium measurement, 
respectively. For staining of VH125.NOD + MD4 B cells, B cells were purified via CD43 negative 
selection before mixing MD4 B cells (~1%) into the VH125.NOD B cells. 
 
4.2.6. Flow cytometry 
Cells were resuspended at 1E7 cells/mL in cold complete medium containing 0.1 % 
sodium azide (NaN3). 100 uL aliquots containing 1E6 cells were stained with fluorescently-
conjugated monoclonal antibodies. Antibodies against the following cell-surface molecules were 
used: B220 (RA3-6B2; BD), IgM-AF488 (B76) and, CD79b-PE (fab; HM79). B76 and HM79 
were produced in the Cambier laboratory and were directly conjugated to fluorochromes according 
to the manufacture's protocol. For the detection of B cells expressing insulin reactive B cell 
receptors, cells were first incubated with or without SAgAIns molecules or hyaluronic acid (HA) 
alone [0.5 ug] for 20 min at 4 degrees C. After two washes and resuspension in 100 uL medium, 
cells were stained with monomeric biotinylated insulin (ins-bt) (1:50), and HEL-AF488 (1:200) 
for VH125.NOD + MD4 experiment, for 20 min at 4 degrees C. Cells were washed again before 
adding anti-B220 (APC, PE, or BUV396), anti-IgM, fab anti-CD79 and, fab anti-biotin-AF647. 
Following final incubation and washing, cells were analyzed on a Fortes X-20 flow cytometer 
(BD) and analyzed using FlowJo software (Tree Star). 
 
4.2.7. Calcium mobilization 
For measurements of relative intracellular free calcium concentration ([Ca2+]i), 125Tg 
RBC-lysed splenocytes (1E7/ mL in complete medium containing 2 % FCS) were incubated with 
or without SAgAIns or HA, for 4 hours at 37°C and 5 % CO2. For an additional hour at RT, cells 
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were simultaneously stained with anti-B220-APC (1:500), fab anti-CD79b-PE (1:500) and, loaded 
with 5 uM Indo-1 acetoxymethyl. After washing once in medium, cells were resuspended at 5E6 
cells/ mL in RT medium in 500 uL aliquots. Indo-1 was excited with a 355-nm UV laser, Ca2+ -
bound Indo-1 was detected with a 379/28 bandpass filter; unbound Indo-1 was detected with a 
524/40 bandpass filter. Relative free intracellular calcium concentration was determined by 
calculating the ratio of bound/unbound Indo-1. After acquiring data for 30 s, to establish a baseline, 
cells were stimulated with the indicated dose of SAgAIns molecules, anti-IgM [B76] and/or 
ionomycin and data collected for an additional 2 min 30 sec. Relative mean [Ca2+]i was measured 
on a Fortessa X-20 flow cytometer and analyzed with FlowJo software.  
 
4.2.8. Statistical Analysis 
GraphPad Prism was used to perform statistical analysis including sigmoidal nonlinear 
regression, ordinary one-way or two-way analysis of variance (ANOVA), and unpaired t-test.  
ANOVA was followed by Tukey’s or Sidak’s post-hoc test, where appropriate. The threshold for 
statistical significance was set to p<0.05. 
 
4.3. Results and Discussion 
Structural Design of Click Soluble Antigen Arrays 
 SAgAs were synthesized by conjugating multiple modified autoantigen (human insulin 
alkyne; Ins-Alk) molecules to a 16 kDa linear polymer hyaluronic acid (HA) to produce the 
following conjugates: low valency lvSAgAIns (2 insulin per HA), medium valency mvSAgAIns (4 
insulin per HA), high valency hvSAgAIns (9 insulin per HA). SAgAs are designed to induce a 
tolerogenic effect by draining into secondary lymphoid organs to access B cells. To achieve the 
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desired immunological effect, SAgAs are designed by following Dintizis’ reported antigen 
structure properties to induce tolerance in B cells: < 100 kDa, flexible, and highly soluble. We 
hypothesize that SAgAs with >5 insulin molecule per HA will induce anergy of insulin-specific B 
cells (IBCs) in the T1D non-obese diabetic (NOD)mouse model, and as a result, re-tolerating the 
mice to the autoantigen insulin and blocking T1D progression. We have previously reported that 
non-cleavable cSAgAPLP constructed via copper-catalyzed azide-alkyne cycloaddition (CuACC) 
covalent linker chemistry through conjugation of homopropargyl-PLP139-151 to HA-azide to be 
superior to hydrolyzable linker chemistry with the same basic components in suppression of 
disease severity in the multiple sclerosis (MS) mouse mode experimental autoimmune 
encephalomyelitis (EAE). Our studies pointed to superior efficacy of non-cleavable SAgAPLP to 
sustained B cell receptor (BCR) engagement, thus prolonged interaction on the cell surface of B 
cells.38 SAgA platform modular antigen design, allows for targeted ASIT in partnership with 
selected antigens using currently validated animal models to predict clinical success of the 
therapeutic SAgA platform. We chose the T1D autoantigen human insulin and the VH125 NOD 
mouse model. We selected CuAAC chemistry to conjugate modified human insulin to modified 
HA. CuAAC chemistry allows for high control over valency and stability. 
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4.3.1. Synthesis and Analytical Characterization of Click Soluble Antigen Arrays 
Both quantitative and qualitative analytical techniques were used to characterize SAgAs 
and their components. The amine pegylated azide (H2N-PEG3-N3) was conjugated to HA via 
EDC/NHS coupling chemistry.  1HNMR was used to quantify azide functionalization of HA-azide 
revealing an average of 41 azides per HA (Figure 34). This was done by integrating a peak form 
the HA backbone, highlighted in yellow, and a peak in HA-N3 that corresponds to a methylene 
peak, highlighted in blue. Due to manual integration performed to determine conjugation and the 
heterogeneity of HA, this analysis should be considered semi-qualitative. Modification of the 
autoantigen human insulin was conducted by conjugating an alkyne linker (Propargyl-N-
hydroxysuccinimidyl ester) via NHS chemistry to furnish insulin-alkyne (Ins-Alk). LC-MS 
verified the successful synthesis of Ins-Alk and further characterization of the modified protein led 
to the identification of the site of modification. LC/MS analysis determined that two species of 
Ins-Alk existed. Either B29 lysine was modified or modification occurred on N-terminus on the A 
chain (Figure 35A; 35B).  
HA 
HA-N3 
Figure 34: 1H NMR spectra of hyaluronic acid (HA) and hyaluronic acid azide (HA-N3).  Peaks used to determine 




Figure 35 (A): Ins-Alk disulfide bonds were reduced via NH4OAc and Dithiothreitol (DDT), run on an LC-MS 
revealed one Ins-Alk species to be modified on the B chain on the lysine residue; (B) shows the second Ins-Alk 





  Initial CuAAC reaction conditions were used to conjugate Ins-Alk to HA-N3 to produce 
SAgAIns (2 Ins per HA). These SAgAs where characterized via RP-HPLC and sent off to our 
collaborators for preliminary biological studies. Upon further synthetic optimization of the 
CuAAC reaction, both medium valency mvSAgAIns (4 Ins per HA) and high valency hvSAgAIns (9 
Ins per HA) were analyzed by RP-HPLC to determine the molecular weight and protein 
conjugation (Figure 36). The complete conjugation of Ins-Alk to HA-N3 can be seen in both Figure 
36A and Figure 36B. It should be noted, two aliquots from each reaction were taken before NaAsc 
was added. One aliquot was used to determine total Ins-Alk in solution and the second was 
analyzed in the same conditions as the reaction mixture without NaAsc to determine protein 
degradation over 24h (~1 Ins-Alk). 
1H/13C Heteronuclear Single Quantum Coherence (HSQC) NMR spectroscopy was used 
to qualitatively confirm the homopropargyl linker on the Ins-Alk (Figure 37A, 37C, green 
resonance; δ(1H) ≈ 2.9 ppm, δ(13C) ≈ 70 ppm). When both human insulin (red resonance) and Ins-
Alk (green resonance) HSQC spectra were superimposed, some residue resonance signals pointed 
towards little to no structural change (Figure 37B, 37D; circled in purple), while distinct 
conformational differences can predominately be seen in the aromatic region for Ins-Alk (Figure 
37B; circled in blue). These differences suggest the installation of the homopropargyl handle 
caused a buried aromatic amino acid (i.e. tryptophan) to surface, thus becoming detectable by 
NMR. Finally, HSQC analysis revealed the absence of the unique resonance signal for the 
homopropargyl linker on Ins-Alk (δ(1H) ≈ 2.9 ppm, δ(13C) ≈ 70 ppm) in both the mvSAgAIns and 




 Circular Dichroism analysis of human insulin was consistent with previously reported 
alpha helical secondary structure (Figure 38A-38D). SAgAIns mostly retained alpha helical 
secondary structure in both neutral (pH 7.4) and acid media (pH 3.0), however, hvSAgAIns appeared 
to lose significant secondary structure in acidic conditions (Figure 38A-D). Further analysis of CD 
data revealed greater loss of alpha helical structure for hvSAgAIns when compared to mvSAgAIns in 
both acid and neutral solutions (Figure 38C, 38D). When directly studying the effect of pH on each 
SAgA, secondary structure in both cases are partial or completely lost at lower pH when compared 
to neutral pH. HSQC NMR analysis in combination with CD data may explain the loss of 
secondary structure of SAgAIns when compared to native human insulin. Alkyne modification 
resulted in a physical change in protein structure that allowed for hydrophobic residues to be 
detected via HSQC NMR. These hydrophobic resides such as tryptophan may increasingly 
interfere with alpha helical structure. In addition, basic amino acids (i.e. arginine) becomes more 
protonated at lower pH, which may result in electrostatic repulsion that could alter the peptide 
secondary structure. 
Figure 36: Reverse-phase analytical high-
performance liquid chromatography (RP-
HPLC) on an xBridge C4 5um (4.6 X 
250mm) gradient 5:95 to 95:5 
(Acetonitrile :Water) @ 214nM; (A) 24 h 
post-NaAsc mvSAgAIns (board black 
trace), overlaid pre-NaAsc (green trace); 
(B) 24 h post-NaAsc hvSAgAIns (board 






































Figure 37: Overlapped HSQC NMR spectra of insulin (red) and Ins-Alk (green) (A-D). Multivalent SAgAs (mvSAgAIns) 
(E) and (hvSAgAIns) F show no resonances from the alkyne peak found only Ins-Alk present in either of the final compounds. 
The alkyne peak found only in Ins-Alk is not found in any of the products, which implies complete no residual unconjugated 
Ins-Alk. HSQC NMR of A focuses on highlighting in a green circle terminal alkyne proton in Ins-Alk. B shows more 
available aromatic residues in Ins-alk (green) when compared to insulin. C and D highlight Similarities (purple circles) and 










A temperature melt plot based on intrinsic fluorescence (Figure 38F) showed an increase 
in nonradiative decay with temperature, which may suggest the absence of tertiary structure. This 
may be explained by the fact that insulin contains three disulfide bonds, which require significant 
amount of energy for a transition occur for an insulin monomer. Finally, dynamic light scattering 
B 
Figure 38: Far-UV Circular Dichroism of (A): medium and high valency SAgAs in phosphate buffer pH 
7.4; (B): medium and high valency SAgAs in water pH 3.0; (C): medium valency SAgAs in phosphate 
buffer pH 7.4 and water pH 3.0;(D): high valency SAgAs in phosphate buffer pH 7.4 and water pH 3.0; 
(E): medium and high valency SAgAs water pH 3.0 temperature melt.; (F): Intrinsic fluorescent 






shows significant size increase for hvSAgAIns, while mvSAgAIns show a predictable increase in size 
(Table 4). This large increase in size in hvSAgAIns may correlate with the partial loss in secondary 
alpha helical structure (Figure 38), where the insulin would now favor intermolecular interactions 
that may lead to aggregation rather than intramolecular interactions. 
 
Table 4. Insulin molar conjugation, as determined by RP- HPLCa . Dynamic light scattering (DLS) 














                      
5.81 0 2.09 ± 0.02 0.08 
HA-N3 
                       
 
      




36.34 2 ---------- ---------- 
mvSAgAIns 
 













a Results are an average of triplicate injections from a single batch preparation.  
b Calculated from RP-HPLC data. MW, molecular weight. 
c Insulin per HA, hyaluronic acid 
d DLS data were collected in triplicate 
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4.3.2. SAgAIns binding and effects on ex vivo IBCs 
In order to address the biological relevance and potential therapeutic application of 
multimeric, insulin-polymer (SAgAIns) molecules, we first asked if SAgAIns are capable of ligating 
B cell receptors (BCR) on the surface of IBCs. To this end, we utilized B cells from 125Tg mice 
in which, by virtue of heavy- and light-chain knock-in, harbor peripheral B cells with an insulin-
fixed receptor repertoire. RBC-lysed, 125Tg splenocytes were first incubated with or without 
SAgAIns (low or high avidity) or hyaluronic acid (HA) alone for 20 min, at 4°C, in complete 
medium containing 0.1 % NaN3. Staining under these conditions prevents the internalization of 
ligated BCR. After being washed, cells were exposed to monomeric biotinylated insulin (ins-bt), 
washed, and subsequently stained with antibodies against B220 (B cells), CD79 (BCR) and, IgM 
(BCR) together with anti-biotin (Insulin). Depicted in Figure 39A, pre-treatment with SAgAIns, 
but not HA alone, blocked binding of ins-bt. Staining, in which ins-bt was omitted, serves as a 
positive control, and staining with no SAgAIns pre-treatment serves as a negative control. In 
addition, neither SAgAIns nor ins-bt bound to non- (B220-) B cells (data not shown). In anticipation 
for experiments in which we re-stimulate SAgAIns tolerated IBCs, we wanted to ensure that 
SAgAIns binding to the BCR does not obscure binding of BCR stimulating antibodies. In this case, 
cells previously exposed to the SAgAIns where subsequently stained with anti-IgM [B76] and anti-
CD79 [HM79]. No change in staining intensity was detected for anti-BCR antibodies in cells pre-
treated with SAgAIns (Figure 39B). Finally, in order to address SAgAIns binding in a more 
physiologic setting, we utilized B cells (CD43-) purified from spleens of VH125.NOD mice in 
which ~1-3% of peripheral B cells bind insulin. To ensure specificity, MD4 B cells (HEL reactive) 
were mixed in at approximately the same frequency as IBCs. As before, cells were pre-treated with 
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SAgAIns or HA alone before being stained with ins-bt/fab anti-bt-AF647 AND HEL-AF488. As 
displayed in Figure 39C, SAgAIns only blocked binding of ins-bt but not HEL-AF488.    
4.3.3. In vitro incubation of IBCs with insulin-SAgA leads to decreased expression of BCR 
and desensitization of the BCR to additional stimulation. 
The ultimate goal of designing SAgAIns is to be used as a potential therapeutic agent for 
treating/preventing the development of T1D. B cells are required for the development of T1D in 
mice and have been strongly implicated in human disease, most likely as antigen presenting cells 
needed for T cell activation in the pancreas.201 Depletion of B cells with an anti-CD20 antibody 
(rituximab) has been shown to delay the progression of disease in humans.202 Similarly, 
tolerization of peripheral B cells via chronic BCR stimulation has been observed to delay disease 
onset in mice.203 Following from this, we hypothesize that tolerizing antigen-(insulin) specific B 
cells may prove to be similarly efficacious in preventing T1D progression. Antigen specific 
A 
B C
Figure 39: Specific binding of SAgAIns to insulin binding cells (IBCs). Both lvSAgAIns and high-avidity ( hvSAgAIns) 
molecules, but not hyaluronic acid (HA) alone, block binding of monomeric biotinylated-insulin to insulin-specific 
(B220+;125Tg) B cells (A). Pretreatment of 125Tg B cells with either SAgAIns or hyaluronic acid does not mask 
epitopes recognized by anti-IgM [B76] nor anti-CD79 [HM79] (B). SAgAIns molecules block binding of insulin-bt to 
insulin specific B cells (CD43-, B220+;VH125.NOD) but not binding of hen egg lysozyme (HEL) to HEL specific B 
cells (CD43-, B220+;MD4) when both cell types are present at similar frequencies (C). Layout gate frequencies 





tolerization comes with the added benefit of allowing the rest of the B cell compartment to remain 
active for fighting infection and responding to vaccination. To ask if SAgAIns is capable of 
tolerizing IBCs, we again utilized B cells from the 125Tg mouse. We first measured intracellular 
calcium mobilization in response to acute stimulation with SAgAIns (Figure 40A). Anti-IgM and 
HA alone were used as positive and negative controls, respectively. SAgAIns stimulated a similar 
calcium flux in comparison to stimulation with anti-IgM (note that 125Tg B cells exclusively 
express IgM). Next, we incubated 125Tg IBCs with or without SAgAIns or HA alone for ~5 hours 
before measuring surface BCR expression and calcium mobilization (Figure 40B, 40C). Pre-
incubation with SAgAIns leads to decreased expression of surface BCR, as measured by CD79b, 
reminiscent of chronically stimulated, anergic B cells found in mice and humans (Figure 40B).201 
Pre-incubation with SAgAIns, but not HA, rendered IBC's refractory to re-stimulation through the 
Figure 40: SAgAIns effects on ex-vivo, insulin-binding cells (IBCs). SAgAIns molecules, but not hyaluronic acid (HA) 
alone, are capable of aggregating B cell receptors (BCR) on insulin specific B cells (125Tg) and stimulating 
extracellular calcium influx (A). 5 hour pre-incubation of IBCs (125Tg) with SAgAIns, but not HA, leads to decreased 
expression of BCR on the surface of IBCs (B). Pre-incubation with SAgAIns renders IBCs refractory to re-stimulation 
through the BCR by anti-IgM [B76] but not to stimulation with the calcium ionophore, ionomycin (io) (C). This 
induced tolerance is independent of the surface expression of BCR (gating in B). Dashed calcium traces represent 
SAgAIns treated (C) or untreated (A) cells stimulated with a 5-fold excess [25 ug] of anti-IgM . Data are representative 





BCR (Figure 40C). This inhibition was not due to masking of the epitope on the BCR recognized 
by B76 (Figure 40B) and was independent of the SAgAIns induced decrease in surface BCR (gating 
in Figure 40B). In addition, SAgAIns incubated cells remained refractory to a 5-fold excess of anti-
IgM stimulation (Figure 13C dashed lines), which resulted in an increased calcium response in 
untreated or HA treated cells (Figure 40A, 40C). Finally, SAgAIns induced desensitization of the 
BCR is independent of IP3 receptor-mediated release of intercellular calcium stores, as stimulation 
with the calcium ionophore, ionomycin, resulted in similar calcium influx in SAgAIns treated, HA 
treated, and untreated cells. This suggests that SAgAIns induced tolerance of IBCs may rely on 
mechanisms observed to be operative in anergic B cells found in mice and in humans.204  
 
4.4. Conclusions 
Both HA-N3 and Ins-Alk were synthesized and verified via various analytical techniques. 
SAgAs were successfully synthesized by conjugating multiple modified autoantigen human 
insulin (Ins-Alk) molecules to a 16 kDa linear polymer hyaluronic acid (HA) to produce the 
following bioconjugates: low valency SAgAIns (2 insulin per HA), medium valency mvSAgAIns (4 
insulin per HA), high valency hvSAgAIns (9 insulin per HA). The mvSAgAIns and hvSAgAIns SAgAs 
were shown to maintain alpha helical structure at physiological pH. They were also successfully 
used to make SAgAIns that silence ex vivo IBCs by inducing refractory B cell receptor signaling. 
SAgAIns binds specifically to insulin-reactive B cells without masking epitopes recognized by 
antibodies against the BCR. Pre-incubation of IBCs (125Tg) with SAgAIns, but not HA, renders 
the BCR desensitized to re-stimulation. This effect is independent of SAgAIns induced decrease in 
BCR expression and is also independent of IP3R-mediated intracellular calcium release. This 
activity is dependent on SAgAIns binding to BCR on the surface of IBCs, and its ability to acutely 
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stimulate these cells. Finally, the biophysical difference between high and low valency SAgAIns 
does not appear to modulate biologic activity, as both molecules produced similar levels of 
receptor blockade and BCR desensitization. In the future these SAgAIns will be tested as 












CHAPTER 5:  




CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
5.1. Introduction 
The need for novel antigen-specific immunotherapies (ASIT) for the treatment of 
autoimmunity is a pressing matter that must be addressed. Bioconjugation techniques such as 
copper-catalyzed azide-alkyne cycloaddition (CuAAC) allow for the facile construction of 
immunological probes to visualize or modulate autoimmunity. This dissertation highlighted in 
detail the two different ASIT approaches for the potential treatment of autoimmune via antigen-
drug conjugates (AgDCs) and soluble antigen arrays (SAgAs) summarized in Section 5.2. The key 
findings in these chapters setup the future directions for these projects, which is discussed in 
Section 5.3. 
 
5.2. Summary of dissertation chapters  
In Chapter 1, an introduction into autoimmunity and current clinically available non-
antigen-specific treatments were presented, along with an overview of the emergence of antigen-
specific immunotherapies (ASIT) as an improved strategy for the treatment of autoimmune 
diseases. Furthermore, a detailed background into the chemistry utilized in this work to construct 
novel antigen-specific probes as potential therapies for autoimmune disorders was also presented. 
Autoimmune diseases afflict 5% of the world’s population and are believed to be caused by the 
loss of tolerance to autoantigen.1 All current treatments for autoimmunity are not antigen-specific 
and either treat symptoms or slow down the progression of the disease. Scientist may be able to 
induce tolerance to autoantigen in individuals afflicted by autoimmune diseases via ASIT. In order 
to construct antigen-specific bioconjugate probes as potential therapies to treat autoimmunity, a 
detailed background and literature review of copper-catalyzed azide-alkyne cycloaddition 
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(CuAAC) chemistry was presented. Key information on CuAAC reactions were discussed, such 
as approaches for installation of azide and alkyne handles into various bioactive molecules, as well 
as, insights into reported bioconjugates used as probes and their ability to modulate biological 
functions. Finally, CuAAC considerations and challenges were discussed to set the foundation for 
the design and optimization for the bioconjugate probes discussed in this work. 
 Chapter 2 presented the synthesis and development of chemical biology tools for probing 
antigen-specific immunotherapy. Specifically, the synthesis of a library of various azide or alkyne 
containing small molecules, modified-mimotopes, and synthetic epitopes, as building blocks for 
Antigen Drug Conjugates (AgDCs) and other immunologically active materials used later in this 
work. Similar to antibody drug conjugates (ADCs), AgDCs are a novel co-delivery ASIT designed 
to deliver a potent drug (cargo), which is chemically linked to an autoantigen (vehicle). Initial 
CuAAC reaction optimization utilizing the multiple sclerosis (MS) mimotope substrate 
propargylglycine-PLP (pPLP) to coumarin-azide (Comarin-N3) was unsuccessful, and it was 
determined that the primary amine in the pPLP handle inhibited the reaction. A redesign of our 
mimotope alkyne handle eliminated the presence of the primary amine and thus homopropargyl-
PLP (hpPLP) was synthesized, characterized, and successfully used in a CuAAC reaction. With 
the success of the new handle design, the N-terminus of a type 1 diabetes (T1D) mimotope p79 
was modified via solid state peptide chemistry to contain a homopropargyl linker (hpP79). CuAAC 
reaction between hpP79 (vehicle) and the immunosuppressant dexamethasone-azide (Dex-N3; 
cargo) was successfully optimized, purified, and ready for potential screening of the AgDC in 
future studies. Also, hpP79 was conjugated to the fluorophore Rhodamine B-azide (Rhod-N3) for 
potential future visualization in the mechanism elucidation of p79 uptake into immune cells. The 
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future direction for the AgDC Dex-p79 was explained in Section 5.3.1. and the future direction of 
AgDCs for other disease indications was discussed in Section 5.3.4. 
 Chapter 3 was inspired by previous research in our group which utilized a novel antigen 
delivery strategy know as Soluble Antigen Arrays (SAgAs) for the potential treatment of MS. 
SAgAs are constructed by conjugating multiple repeating autoantigen to a hydrophilic linear 
polymer backbone hyaluronic acid (HA). The technology was repurposed as a potential therapeutic 
for T1D by using the T cell stimulatory mimotope p79 from chapter 2. Similar to previous work 
published in the Berkland group,64, 154 two different linker chemistries were used to conjugate p79 
to HA. Either a non-hydrolyzable ‘click” CuAAC linker chemistry to furnish cSAgAp79 or 
hydrolyzable aminooxy chemistry was used to produce SAgAp79. Our ASIT technology was 
characterized via various analytical techniques: high-performance liquid chromatography (HPLC), 
nuclear magnetic resonance spectroscopy (NMR), circular dichroism (CD), dynamic light 
scattering (DLS), and fluorescence. The biophysical characterization revealed a similar secondary 
structure of peptides conjugated to SAgAs as their parent peptide hpP79 and aoP79. No definitive 
tertiary structure was detected for either cSAgAp79 or SAgAp79. The specificity and efficiency of 
T cell stimulation by these SAgAs was demonstrated by in vitro treatment of splenocytes from 
BDC2.5 versus NOD mice, and we identified conventional dendritic cells (cDCs) as the most 
efficient type of APCs responsible for uptake and presentation of SAgA-derived epitopes to T 
cells. We also observed that cSAgAp79 are more stimulatory than SAgAp79, a property that appears 
to be more associated with the N-terminal peptide modification than their peptide release 
properties. Future work for p79 containing SAgAs was discussed in Section 5.3.2. 
Chapter 4 focused on alternative T1D therapy SAgA constructed by conjugating full-length 
human insulin protein to HA. Unlike the p79-SAgA work, only CuAAC chemistry was used to 
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construct SAgAIns and three different valences of autoantigen insulin (2, 4, 9) per HA were 
synthesized. Analysis of CD data reveled that both medium valency (mvSAgAIns) and high valency 
(hvSAgAIns) SAgAs were shown to maintain alpha helical structure at physiological pH and no 
higher order structure was detected by fluorescence for either SAgAIns. SAgAIns ex vivo were able 
to ligate B cell receptor (BCR) on the surface of insulin-binding cells IBCs in B cells from both 
125Tg (NOD) and VH125.NOD mice. The biophysical difference between SAgAIns does not 
appear to modulate biologic activity, as both molecules produced similar levels of receptor 
blockade and BCR desensitization. The future direction of this work will be discussed in Section 
5.3.3. 
 
5.3. Future directions 
5.3.1. Adjusting design of AgDCs to improve solubility Dex-p79 
First, Dex-p79 AgDCs needs to be screened in order to determine if specificity of the 
peptide is retained in vitro. If successful, drug 
release and stability studies will be performed. 
Then, the AgDCs need to be studied to determine 
if they can induce an antigen-specific immune 
response. If specificity and immune tolerance is 
possible, Rhod-p79 can be used to determine the 
potential mechanism of action for Dex-p79. 
However, it should be highlighted that solubility of 
Dex-p79 was poor in aqueous solution. In order to improve solubility, either an alternative water-
soluble drug should be used (ie. 5-Fluoro-5’-deoxycytidine; 5'-DFCR)205 and/or a hydrophilic 
Figure 41: Hydrophilic drug 5-Fluoro-5’-




linker (i.e. PEGylated or Sulfonated) should be used (Figure 41). AgDCs for other disease 
indications are also possible with the use of other autoantigens (see Section 5.3.4). 
 
5.3.2. Continued p79-SAgA development 
The in vitro success of both cSAgAp79 and SAgAp79 in splenocytes from BDC2.5 mice has 
promoted future in vivo studies. Furthermore, stability studies can be performed to better 
understand the potential bioavailability of the p79-containing SAgAs in vivo. SAgAs can be 
redesigned by making structural changes. Dintzis and coworkers reported that a tolerogenic 
immune response could be induced by varying both the peptide valency and/or polymer backbone. 
Therefore, modification of p79-containing SAgAs’s valency and polymer backbone in the future 
could potentially improve its efficacy.206 Valency can be controlled by either changing the reactive 
azides available on the HA on cSAgAp79, or optimizing the reaction conjugation (i.e. time, temp, 
stoichiometry, etc.) to conjugate less p79 per HA for SAgAp79 and cSAgAp79. Finally, if lower 
valency maintains or increases potency, then different polymer backbone such as shorter HA or 
multi-arm-PEGylated polymers may be used to improve bioavailability and potency.167 The multi-
arm-PEGylated system may present different modulatory effects due to its ability to contour 
antigen-specific cell surfaces in a multidirectional manner, unlike the linear SAgAs used in this 
work. 
 
5.3.3. Continued SAgAIns development 
The SAgAIns have shown potential in vitro, but require further testing in vivo to determine 
if SAgAIns are capable of improve the disease state of VH125.NOD mice. These studies would 
require a significant amount of human insulin, and therefore may require optimization to improve 
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synthesis and purification of Ins-Alk. HPLC analysis of crude Ins-Alk resulted in 60% yield of the 
desired product, however, upon isolation of Ins-Alk the final yield dropped to 32%. SAgAIns was 
able to induce tolerance with only2 insulins per HA, thus, maybe simply tethering two insulin 
molecules via a bifunctional hydrophilic linker (e.g. PEGylated), similar potency may be observed. 
Such bioconjugation would significantly reduce the analytical characterization for future scientist 
in our group. 
 
5.3.4. Alternative Autoantigens for Future deployment of AgDCs and SAgAs 
This thesis presented the synthesis and characterization of chemical biology probes as 
potential therapeutics for T1D. Utilizing the same basic design of the AgDCs or SAgAs, it may be 
possible to design, synthesize, and characterize chemical biology probes for other autoimmune 
diseases. A few examples are listed in Table 5 below. 
Table 5. A few examples of potential autoantigen for antigen-specific immunotherapies (ASIT) 
for both AgDCs and SAgAs 
Autoimmune Disease Antigen 
Multiple Sclerosis MBP, MOG 
 



















 Both peptides and full-length protein autoantigen can be utilized in our ASIT design, but a 
few considerations must be taken into account for the construction of future AgDCs or SAgAs for 
other autoimmune diseases. First, the best antigen for modification must be determined via epitope 
screening. Then for full length proteins, possible site for selective modification without losing 
efficacy must be determined. Furthermore, the solubility of the autoantigen selected must be taken 
into consideration to avoid inducing undesired pro-inflammatory responses as seen in vaccines. 
Finally, a well characterized animal model to test the efficacy of the antigen-specific chemical 
biological probes is needed. 
 
5.4. Conclusions 
In this dissertation, an azide/alkyne library of small molecules, modified peptides, and 
polymers were synthesized and used to construct various bioconjugates to visualize or modulate 
immunological systems.  The use of CuAAC chemistry allowed for the rapid construction of 
bioconjugates, which were efficacious in their respective animal models. Finally, a significant 
amount of work is left for the future elucidation of the mechanism or the novel antigen-specific 
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